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Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable 
disorder characterised by progressive degeneration of the right ventricular myocardium, 
arrhythmias and an increased risk of sudden death at a young age.  Fourteen chromosomal 
loci have been linked to ARVC and nine disease genes have been identified.  Linkage 
analysis of a South African family was previously performed at ARVC loci 1 to 6.  ARVC 
loci 1 to 5 were excluded as disease loci in this family based on lack of evidence for 
linkage.  However, a peak lod score of 2.93 was obtained for the ARVC-6 locus which is 
highly suggestive of linkage.  Subsequently another locus (ARVC-7) and five ARVC 
disease genes (ARVC loci 8 to 12) have been reported.  The aim of this project was to 
identify the disease gene that causes ARVC in this family. 
 
Methods: Exclusion mapping was performed in this family at the ARVC-7 locus and for 
the five ARVC disease genes.  The positional candidate genes in the ARVC-6 locus were 
prioritised for mutation screening using several existing bioinformatics tools and tissue 
expression data.  Fifteen genes were screened for mutations, in two affected and two 
unaffected family members, by sequencing, High Resolution Melt (HRM) and Denaturing 
High Performance Liquid Chromatography (DHPLC).  Copy-number analysis of one 
affected family member and whole-genome single nucleotide polymorphism (SNP) 
linkage analysis of 12 family members was performed.  
 
Results: The ARVC-7 locus and the five genes were excluded from causing disease in this 
family.  Mutation screening of 15 genes in the ARVC-6 locus identified 36 sequence 
variants (SVs).  Twenty-nine SVs have been reported as SNPs on the NCBI SNP database 
and seven SVs were novel.  Only one SV, c.1641A>G in DCLRE1C, was found in the two 
affected family members and was not present in the two unaffected family members 
screened.  This single base substitution results in a synonymous amino acid change, the 
significance of which is unknown.  No copy-number variation (CNV) was found in the 
ARVC-6 region.  Whole-genome SNP linkage analysis identified a peak multipoint lod 











and correlates with the ARVC-6 locus.  Haplotype analysis of the chromosome 4 region 
identified a linkage interval of ~7.18Mb.   
 
Conclusion: Comprehensive mutation screening of the ARVC-6 locus on chromosome 10 
has not identified any overt disease-causing mutations.  The synonynous substitution 
found in DCLRE1C requires further investigation.  Whole-genome SNP linkage analysis 
identified a novel locus for ARVC on chromosome 4 which is likely to harbour the disease 



























1 INTRODUCTION  
1.1 Cardiovascular Disease  
Cardiovascular diseases (CVDs) are the number one cause of death in the world (WHO).  
Over 80% of CVD deaths occur in low- and middle-income countries (WHO).  In South 
Africa, the National Burden of Disease Study in the year 2000 reported CVD as the 
second most important cause of death, accounting for 17% of all deaths (Bradshaw et al., 
2003).  The Heart of Soweto Study reported 1593 new cases of CVD were diagnosed in 
2006 at the Chris Hani Baragwanath Hospital in Soweto, South Africa (Sliwa et al., 2008).  
The most common primary diagnosis in this group was heart failure. 
 
1.2 Heart Failure 
In developed countries, the crude incidence of heart failure is estimated to range from one 
to five cases per 1000 per year and the crude prevalence is estimated as three to 20 per 
1000 (Mendez and Cowie, 2001).  Coronary artery disease is the most common cause of 
heart failure in these countries.  There are no published population-based incidence or 
prevalence studies of heart failure from developing countries.  Hospital-based studies in 
Africa indicate that heart failure contributes to 3-7% of admissions due to CVD (Mayosi, 
2007).  In sub-Saharan Africa, heart failure is mainly due to non-ischaemic causes such as 
hypertension, rheumatic heart disease, pericarditis and cardiomyopathy (Mayosi, 2007). 
 
1.3 Cardiomyopathy  
The European Society of Cardiology Working Group on Myocardial and Pericardial 
Diseases defines cardiomyopathy as “a myocardial disorder in which the heart muscle is 
structurally and functionally abnormal, in the absence of coronary artery disease, 
hypertension, valvular disease and congenital heart disease sufficient to cause the 
observed myocardial abnormality” (Elliott et al., 2008).  There are five types of 
cardiomyopathy namely: dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy 












ventricular non-compaction (LVNC)) and arrhythmogenic right ventricular 
cardiomyopathy (ARVC). 
 
1.4 Arrhythmogenic Right Ventricular Cardiomyopathy 
(ARVC) 
ARVC is characterised by fibrofatty replacement of the right ventricular myocardium 
(Marcus et al., 2010).  Figure 1-1 shows the macroscopic structure, magnetic resonance 
image (MRI) and histopathology of a heart with ARVC.  Four stages of disease 
progression have been documented: an early concealed phase, overt electrical disorder, 
isolated right heart failure and biventricular pump failure (Sen-Chowdhry et al., 2010).  In 
the concealed phase, structural changes may be absent or subtle and confined to the right 
ventricular inflow tract, outflow tract or apex which is known as the “triangle of 
dysplasia” (Marcus et al., 2010).  Individuals are often asymptomatic but may be at risk of 
sudden cardiac death (SCD), particularly during strenuous activity.  The concealed phase 
is followed by an overt electrical disorder.  Individuals present with symptomatic 
ventricular arrhythmia of RV origin and RV structural abnormalities are discernible on 
imaging (Sen-Chowdhry et al., 2010).  Disease progression leads to global RV dysfunction 
and isolated right heart failure.  Localised involvement of the left ventricle (LV) may 
occur.  Progressive LV involvement leads to biventricular pump failure.  Left–dominant 
and biventricular subtypes have also been recognised (Sen-Chowdhry et al., 2007b). 
 
It is thought that ARVC may be a milder form of Uhl’s anomaly.  This disease is 
characterised by partial or complete absence of the right ventricular myocardium and it 
presents in infancy as heart failure.  The pathogenesis of Uhl’s anomaly has not been 


























(John et al., 2004) 
Figure 1-1: A. A short axis slice of a heart with ARVC.  Yellow streaks of fat are 
indicated with arrows.  B. A MRI, of the same slice, which shows an increased signal 
intensity corresponding to the yellow streaks seen in A.  C&D. A histopathology specimen 
taken from the RV showing large numbers of fat cells.  LV = left ventricle, RV = right 
ventricle  
 
1.4.1 Historical Background of ARVC 
In 1961, Dalla-Volta and colleagues described an “auricularization of the right ventricular 
curve” in a patient with “primitive endocardial fibrosis” (Dalla Volta et al., 1961; Paul et 
al., 2003).  In 1977, Fontaine and colleagues consolidated these findings and called it 
“right ventricular dysplasia” (i.e. an abnormality of development) (Michael et al., 2004; 
Paul et al., 2003).  Once the cause of this disease was identified as progressive myocardial 
loss, the term “cardiomyopathy” was considered more appropriate than “dysplasia” 
(Thiene et al., 1991).  In 1995, ARVC was added to list of cardiomyopathies by the 
WHO/ISFC Task Force (Richardson et al., 1996).  The first case series of ARVC in South 












1.4.2 Epidemiology of ARVC 
The exact prevalence of ARVC is unknown due to incomplete penetrance of the disease 
and under diagnosis by clinicians and pathologists (Paul et al., 2003; Wolfe and Corwin, 
2005). 
 
The prevalence of ARVC was determined as 1 in 1000 inhabitants served by the 
Academic Teaching Hospital in Quedlinburg, Germany (Peters et al., 2004).  It was a 
retrospective study over a 5-year time period which revealed a much higher prevalence 
than that of other centres. 
 
In Italy, preliminary studies showed ARVC to account for 20% of all sudden deaths in 
individuals under the age of 35 years and 27% of sudden deaths in young athletes 
(Corrado et al., 1990; Thiene et al., 1988).  In a 21-year prospective cohort study, ARVC 
and coronary artery disease (CAD) were associated with the greatest risk of sudden death 
in Italian athletes (Corrado et al., 2003).  In the USA, ARVC accounts for only 2% of 
sudden death in athletes while HCM is the most common cause of sudden death in athletes 
causing 30% of cases (Maron et al., 1996). 
 
The regional variation in ARVC prevalence may be due to two reasons.  First, the genetic 
predisposition, dietary pattern and environmental conditions of Italians are different from 
those of Americans (Williams and Chen, 2003).  Second, in the 21-year Italian study, the 
examination of all hearts was performed by the same team of experienced cardiovascular 
pathologists (Corrado et al., 2003). 
 
The scarcity of reports on ARVC in Africa is thought to be due to the lack of sophisticated 
cardiac electrophysiology facilities and expertise required for the diagnosis of the disease 
(Sliwa et al., 2005).  A report from the ARVC Registry of South Africa suggests that 
ARVC occurs in all segments of the population and that its clinical features are similar to 













1.4.3 Diagnosis of ARVC 
In 1994, an “International Task Force for ARVC” proposed standardised diagnostic 
criteria (McKenna et al., 1994).  The diagnosis is based on major and minor criteria that 
encompass clinical, structural and functional features (Hodgkinson et al., 2005).  A patient 
is diagnosed with ARVC if they have two major criteria, one major plus two minor criteria 
or four minor criteria from different diagnostic categories (McKenna et al., 1994).  
Subsequently, the Task Force Criteria have been modified to incorporate new knowledge 
and technology to improve sensitivity for early and familial disease (Marcus et al., 2010).   
 
1.4.4 Treatment of ARVC 
Treatment of ARVC is focused on controlling ventricular arrhythmias and preventing 
sudden death (Frias, 2005).   
 
Patients with well-tolerated, non-life-threatening ventricular arrhythmias are treated with 
anti-arrhythmic drugs.  Beta-blockers alone or in combination with sotalol or amiodarone 
may be used (Campbell, 2005).  ARVC patients should avoid class Ia antiarrhythmic 
agents such as propafenone which has been associated with incessant ventricular 
tachycardia in these patients (Michael et al., 2004). 
 
Patients with life-threatening ventricular arrhythmias are best treated with an implantable 
cardioverter-defibrillator (ICD).  A study by Hodgkinson et al. demonstrated that ICD 
therapy improved survival of males.  The effectiveness of ICD therapy in preventing 
sudden cardiac death in women was however not demonstrated (Hodgkinson et al., 2005).  
This supports the clinical observation of a milder disease expression and better long-term 
prognosis of ARVC in women (Wichter and Breithardt, 2005).   
 
Patients with frequent ventricular tachycardias or ICD shocks despite optimal 
antiarrhythmic therapy are candidates for radiofrequency catheter ablation (RFA) (Herren 












In patients with severe right ventricular or biventricular failure, treatment consists of 
pharmacologic therapy for heart failure and heart transplantation (Frias, 2005; Michael et 
al., 2004). 
 
1.4.5 Genetics of ARVC 
ARVC is familial in 30 to 80% of cases and it is inherited in an autosomal dominant or an 
autosomal recessive manner (Gerull et al., 2004).  Fourteen chromosomal loci have been 
linked to ARVC and nine disease genes have been identified, namely plakoglobin (JUP), 
cardiac ryanodine receptor (RyR2), desmoplakin (DSP), plakophilin-2 (PKP2), 
transforming growth factor-β3 (TGFβ3), desmoglein-2 (DSG2), desmocollin-2 (DSC2), 
transmembrane protein 43 (TMEM43) and desmin (DES).  The most frequent mutations 
occur in desmoplakin, plakophilin-2 and desmoglein-2 (Herren et al., 2009).  The 





















Gene & OMIM identifier Reference 
ARVC-1 
 
(Rampazzo et al., 1994) 107970 
 
14q23-q24 AD Transforming Growth Factor-β3 (TGFβ3) (190230) (Beffagna et al., 2005) 
ARVC-2 (Rampazzo et al., 1995) 600996 
 
1q42-q43 AD Cardiac Ryanodine Receptor (RyR2) (180902) (Tiso et al., 2001) 
ARVC-3 (Severini et al., 1996) 602086 14q12-q22 AD None - 
ARVC-4 (Rampazzo et al., 1997) 602087 2q32.1-q32.3 AD None - 
ARVC-5 (Ahmad et al., 1998) 604400 3p23 AD Transmembrane Protein 43 (TMEM43) (612048) (Merner et al., 2008) 
ARVC-6 (Li et al., 2000a) 
(Matolweni et al., 2006) 
604401 10p12-p14 AD None - 
ARVC-7 (Melberg et al., 1999) 609160 10q22.3 AD None - 




Desmoplakin (DSP) (125647) (Rampazzo et al., 2002) 
(Alcalai et al., 2003)  




Plakophilin-2 (PKP2) (602861) (Gerull et al., 2004) 
(Awad et al., 2006) 
               ARVC-10 - 610193 18q12.1 AD Desmoglein-2 (DSG2) (125671) (Pilichou et al., 2006) 
ARVC-11 - 610476 18q12.1 AD Desmocollin-2 (DSC2) (125645) (Syrris et al., 2006)  
(Heuser et al., 2006) 
ARVC-12 - 611528 17q21 AD Plakoglobin (JUP) (173325) (Asimaki et al., 2007) 
Naxos disease (Coonar et al., 1998) 601214 
 
17q21 AR Plakoglobin (JUP) (173325) (McKoy et al., 2000) 
ARVC/APC (Frances et al., 1997) 115650 14q24-qter AR None - 
ARVC-13 - nm 2q35 AD Desmin (DES) (125660) (van Tintelen et al., 2009) 
 
Note:  The types of ARVC (i.e. ARVC-1 to -13) are classified based on the different loci mapped for the condition (Dokuparti et al., 2005). 
APC = Anterior Polar Cataract; OMIM = Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/omim/); AD = Autosomal Dominant; AR = Autosomal 













1.4.5.1 Desmosomal genes 
Five out of the nine ARVC genes, namely plakoglobin, desmoplakin, plakophilin-2, 
desmoglein-2 and desmocollin-2, encode cell junction proteins that are found in the 
desmosome.  ARVC has therefore been called “a disease of the desmosome” (Gerull et al., 
2004).  
 
Desmosomes belong to a class of intercellular junctions called “anchoring junctions” (Yin 
and Green, 2004).  They are found primarily in epithelial tissues but they are also present 
in the meninges, the dendritic reticulum cells of lymph node follicles and the myocardium.  
Desmosomes provide mechanical integrity to these tissues by anchoring intermediate 
filaments (IFs) to sites of strong adhesion (McGrath, 2005).   
 
Desmosomes contain proteins from three distinct gene families, namely: 
1. cadherins: desmogleins (DSG1-4) and desmocollins (DSC1-3) 
2. armadillo proteins: plakoglobin, plakophilins (PKP1-3) and p0071  
      (also known as PKP4) 
3. plakins: desmoplakins I and II, plectin, envoplakin, periplakin and epiplakin  
(McGrath, 2005; Yin and Green, 2004).   
 


























(McGrath, 2005)  
Figure 1-2: Desmosome ultrastructure and molecular model in human skin. 
A. An electron micrograph of a desmosome in human skin, showing the regions of the junction, namely: the inner dense plaque (IDP), the outer 
dense plaque (ODP), the plasma membrane (PM) and the dense midline (DM).  B. A molecular model which depicts the relative organisation of 
the major desmosomal proteins.                       
IDP 
PM 













1.4.5.1.1 Plakoglobin (JUP) 
In 2000, plakoglobin was identified as the first ARVC disease gene.  McKoy and 
colleagues reported a homozygous two base pair deletion in plakoglobin as the cause of 
Naxos disease (McKoy et al., 2000).  Naxos disease was first described in 1986 in families 
originating from the Greek island of Naxos (Protonotarios et al., 1986).  This disease is an 
autosomal recessive form of ARVC associated with thickening of the palms and soles 
(palmoplantar keratoderma) and woolly hair (Protonotarios et al., 2002).  The skin and 
hair phenotype is fully expressed from early infancy, while the cardiac abnormalities are 
100% penetrant by adolescence (Protonotarios et al., 2001).  In 2007, the first dominant 
mutation in plakoglobin was identified in a German family with ARVC but with no 
cutaneous abnormalities (Asimaki et al., 2007).   
 
1.4.5.1.2 Desmoplakin (DSP) 
A genome-wide scan and mutation screening in a family with autosomal dominant ARVC 
identified desmoplakin as a ARVC disease gene (Rampazzo et al., 2002).  A year later, a 
homozygous mutation in desmoplakin was identified in a family with autosomal recessive 
ARVC, pemphigous-like skin disorder and woolly hair (Alcalai et al., 2003).   
 
1.4.5.1.3 Plakophilin-2 (PKP2) 
Gerull and colleagues were the first to report plakophilin-2 as an ARVC disease gene 
(Gerull et al., 2004).  They identified heterozygous mutations in 32 of 120 unrelated 
probands of western European descent (27%).  Awad and colleagues reported the first case 
of  recessive ARVC due to a homozygous cryptic splice mutation in PKP2 (Awad et al., 
2006).  The patient had no significant cutaneous abnormalities. 
 
1.4.5.1.4 Desmoglein-2 (DSG2) 
Desmoglein-2 is the only desmoglein isoform expressed in cardiac myocytes.  Pilichou 
and colleagues therefore screened this gene in 80 unrelated ARVC probands and identified 













1.4.5.1.5 Desmocollin-2 (DSC2) 
Syrris and colleagues were the first to report desmocollin-2 as an ARVC disease gene  
(Syrris et al., 2006).  They screened 77 probands and identified two heterozygous 
mutations in 4 probands.  A month later, Heuser and colleagues reported a mutation screen 
of DSC2 in 88 probands.  In one proband they identified a heterozygous transition that 
affects the conserved 3’ splice-acceptor site of intron 5.  Alternatively, a cryptic splice-
acceptor site in exon 6 is used which causes a frameshift and a premature stop codon 
(Heuser et al., 2006). 
 
Compound and double/digenic heterozygosity has also been identified in the desmosomal 
genes (Bauce et al., 2010; Xu et al., 2010). 
 
1.4.5.2 Extradesmosomal genes 
1.4.5.2.1 Cardiac Ryanodine Receptor (RyR2) 
RyR2 is a calcium (Ca
2+
)-release channel found on the sarcoplasmic reticulum (an 
intracellular Ca
2+ 
storage organelle).  In the heart, Ca
2+ 
regulates muscle contraction and 
electrical signals that determine the cardiac rhythm.  RyR2 is required for excitation-
contraction (EC) coupling and maintaining intracellular calcium homeostasis (Chelu et al., 
2004; Marks, 2000; Tiso et al., 2001). 
 
Mutations in RyR2 cause ARVC-2 (Tiso et al., 2001) and catecholaminergic polymorphic 
ventricular tachycardia (CPVT) (Priori et al., 2001).  CPVT is characterised by stress-
induced, bidirectional ventricular tachycardia in the absence of structural heart disease 
(Laitinen et al., 2001; Priori et al., 2001).  ARVC-2 differs clinically from the other types 
of ARVC due to the presence of effort-induced ventricular arrhythmias, high penetrance 
and 1:1 male:female ratio among affected patients (Tiso et al., 2001). 
 
It has been hypothesised that mutations in RyR2 cause ARVC-2 by altering the ability of 
the channel to remain closed which leads to Ca
2+ 














will in turn lead to arrhythmias and an imbalance of intra-cellular Ca
2+ 
can trigger 
apoptosis (Chelu et al., 2004; Dokuparti et al., 2005). 
 
1.4.5.2.2 Transforming Growth Factor-β3 (TGFβ3) 
In 2005 Beffagna and colleagues reported transforming growth factor-β3 (TGFβ3) as the 
disease gene involved in ARVC-1.  TGFβ3 belongs to a group of regulatory cytokines 
which are important in development and tissue homeostasis.  They identified a nucleotide 
substitution in the 5’ untranslated region (UTR) of an ARVC-1 family and in the 3’ UTR 
of an unrelated ARVC patient.  Neither nucleotide change was found in 300 control 
subjects and in vitro expression assays showed mutated UTRs to be about 2.5-fold more 
active than wild-types (Beffagna et al., 2005). 
 
In an editorial, Nattel and Schott mention a number of issues that need to be resolved 
before TGFβ3 overexpression can be accepted as the molecular basis of ARVC-1.  Their 
first concern is that two families with linkage to ARVC-1 do not contain 
TGFβ3 mutations.  The in vivo overexpression of TGFβ3 needs to be confirmed in the 
mutation carriers and the biological connection between TGFβ3 overexpression and 
ARVC needs to be established.  TGFβ3 is ubiquitously expressed yet mutations in this 
gene result in only a cardiac phenotype (Nattel and Schott, 2005). 
 
1.4.5.2.3 Transmembrane Protein 43 (TMEM43)  
A missense mutation was identified in TMEM43 in fifteen unrelated ARVC families from 
the island of Newfoundland, Canada (Merner et al., 2008).  The mutation occurs within a 
highly conserved transmembrane domain.  TMEM43 contains a response element for an 
adipogenic transcription factor, PPARγ, which may explain the fibrofatty replacement of 
the myocardium.  Merner and colleagues concluded that ARVC, due to this TMEM43 















1.4.5.2.4 Desmin (DES) 
Desmin is a major intermediate filament protein of skeletal and cardiac muscle.  Van 
Tintelen and colleagues reported five Dutch families with an identical desmin mutation.  
An investigation of the clinical and pathologic characteristics of 27 patients identified two 
patients who fulfilled the diagnostic criteria for ARVC (van Tintelen et al., 2009). 
 
1.5 ARVC research in South Africa 
The ARVC Registry of South Africa was established in 2004 by the Cardiac Arrhythmia 
Society of Southern Africa (CASSA) (Latib et al., 2004).  Suspected cases of ARVC are 
referred to the co-ordinating centre in the Cardiac Clinic at Groote Schuur Hospital, Cape 
Town.  As of April 2009, 50 unrelated ARVC patients were enrolled in the registry 
(Watkins et al., 2009). 
 
Genetic analysis was previously performed on the largest family enrolled in the registry 
(family ACM 2) (Matolweni et al., 2006).  This family is of northern European descent 
and ARVC is inherited in an autosomal dominant manner.  When genetic analysis began 
on this family there were only six known ARVC loci and no disease genes had been 
identified yet.  In order to identify the disease-causing gene in this family, the family 
members were genotyped with microsatellite markers at the six known loci.  ARVC loci 1 
to 5 were excluded as disease loci and a peak lod score of 2.93 was obtained for the 
ARVC-6 locus.  According to Matolweni and colleagues “lod score simulation analysis 
showed that 2.93 is the highest lod score that could be obtained for this pedigree” 
(Matolweni et al., 2006).  Two positional candidate genes, integrin alpha 8 (ITGA8) and 
FERM domain containing 4 (FRMD4A), and a non-positional candidate gene, laminin 
receptor 1 pseudogene 6 (LAMR1P6), were screened for mutations.  No disease-causing 
mutations were identified in these genes. 
 
The current genetic research is focused on screening ARVC patients, enrolled in the 
registry, for mutations in the five desmosomal genes (i.e. plakophilin-2 (Watkins et al., 













1.6 The benefits of genetic elucidation of ARVC 
Clinical diagnosis of ARVC can be difficult to make but genetic testing can aid diagnosis 
(Sen-Chowdhry et al., 2007a).  The more is known about the genetics of this disease the 
more useful genetic testing will become as a diagnostic tool.  If a mutation is identified in 
the proband, cascade screening of the family can be performed.  This will identify the 
gene-carriers allowing targeting of clinical resources and avoiding lifelong clinical 
reassessment of extended families (Sen-Chowdhry et al., 2007a).  Genetic counselling of 
patients is currently problematic due to incomplete penetrance and variable expressivity 
(Sen-Chowdhry et al., 2007a).  Studies to determine mutation-specific cardiac features are 
therefore needed for accurate risk stratification (Merner et al., 2008).  The identification of 
all ARVC disease genes will aid elucidation of the pathogenic pathway leading to the 
condition and identify targets for disease-modifying therapy (Dokuparti et al., 2005; Sen-
Chowdhry et al., 2010). 
 
1.7 The aim of this project 
The aim of this project was to identify a novel disease gene that causes ARVC in the 












2 EXCLUSION MAPPING 
2.1 Introduction 
Linkage analysis of family ACM 2 was previously performed at six known ARVC loci 
(Matolweni et al., 2006).  ARVC loci 1 to 5 were excluded as disease loci in this family 
based on lack of evidence for linkage.  However, a peak lod score of 2.93 was obtained for 
the ARVC-6 locus which is highly suggestive of linkage.  When this project was started, 
another locus (ARVC-7) and five ARVC disease genes (i.e. desmoplakin, plakophilin-2, 
desmoglein-2, desmocollin-2 and plakoglobin) had since been reported.  The 
chromosomal positions of the loci are given in Table 2-1.  The aim of this study was to 
exclude ARVC-7 and the five genes as the disease-causing loci for this family. 
 
Table 2-1: ARVC loci and genes identified for exclusion mapping in family ACM 2 
Type of ARVC Chromosome Gene identified 
ARVC-7 10q22.3 None 
ARVC-8 6p24 Desmoplakin (DSP) 
ARVC-9 12p11 Plakophilin-2 (PKP2) 
ARVC-10 18q12.1 Desmoglein-2 (DSG2) 
ARVC-11 18q12.1 Desmocollin-2 (DSC2) 
ARVC-12 and  
Naxos disease 




Twenty family members provided informed consent to participate in genetic studies to 
identify the causal mutation (Appendix A) and donated blood for DNA extraction.  The 
clinical evaluation of the family members is described in Matolweni et al., 2006.  The 
blood specimens and consent forms were sent to the molecular genetics laboratory of the 












captured onto the Human Genetics Laboratory Database and a laboratory reference code 
was assigned to each specimen to ensure confidentiality.  DNA was extracted from 
lymphocytes by a research assistant using the PUREGENE
TM 
DNA Isolation Kit (Gentra 
Systems, Adcock Ingram Scientific). 
 
2.2.2 Polymerase Chain Reaction (PCR) 
2.2.2.1 Primer Design  
Three microsatellite markers were chosen to genotype the ARVC-7 locus as the disease 
gene has not yet been identified.  These microsatellite markers were found to segregate 
with ARVC in the family in which the locus was mapped (Melberg et al., 1999).  The 
Ensembl database (http://www.ensembl.org/index.html) was used to select a single 
published microsatellite marker within or in close proximity to each of the five disease 
genes.  PCR primer sequences (Department of Molecular and Cell Biology, UCT) for the 
microsatellite markers were obtained from the UniSTS database on NCBI 
(http://www.ncbi.nlm.nih.gov/unists/) and are given in Appendix B (set one).  Reverse e-
PCR (http://www.ncbi.nlm.nih.gov/sutils/e-pcr) was used to check that the primers were 
specific for the amplification of the microsatellite markers.  If the tandem repeat of a 
microsatellite marker was not indicated on NCBI, the Tandem Repeats Finder software 
(version 2.02) was used to identify the tandem repeat. 
 
Three of the eight microsatellite markers were found to be uninformative for this family, 
namely D6S1547 (DSP), D12S1692 (PKP2) and AFM344ZD5 (DSC2).  All CA and GT 
dinucleotide repeats, with a minimum of 20 repeats, were identified within 300 kb either 
side of the DSP, PKP2 and DSC2 genes.  Two new microsatellite markers were designed 
for each of these three genes – one of which had to be within the gene if the published 
microsatellite marker was not located within the gene.  Primers were designed using 
Primer 3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_results.cgi).  In order to 
multiplex the six microsatellite markers (i.e. genotype the six microsatellite markers 
together), primers were chosen so that each microsatellite marker had a different PCR 
product size and the fluorescent tags were assigned based on PCR product size.  The 
sequence of these primers (Department of Molecular and Cell Biology, UCT) is given in 












2.2.2.2 PCR Optimisation  
PCR was optimised using the temperature gradient function on either the Labnet 
MultiGene Thermal Cycler (Whitehead Scientific) or the Px2 Thermal Cycler (Thermo 
Electron Corporation) (Appendix C).  The PCR products were separated by gel 
electrophoresis through a 1% agarose gel and visualised using ethidium bromide 
(Appendix D).  A volume of 5µl of PCR product was mixed with 3µl Green GoTaqR Flexi 
Buffer (Promega, Whitehead Scientific) (Appendix E) and electrophoresed alongside 
650ng 100bp DNA Ladder (Promega, Whitehead Scientific) (Appendix F).  Four 
microsatellite markers (AFM344ZD5, D18S36, D10S2327 and D10S201) had small PCR 
product sizes (between 132bp and 230bp).  These PCR products were separated by gel 
electrophoresis through a 3% MS-8 Agarose gel and visualised using ethidium bromide 
(Appendix D).  Agarose MS-8 was used as it improves the resolution of small PCR 
products.  A volume of 5µl of PCR product was mixed with 3µl sucrose solution 
(Appendix E) and electrophoresed alongside 0.5µg Low Molecular Weight DNA Ladder 
(New England Biolabs) (Appendix F).  Sucrose was used instead of agarose loading dye as 
the bromophenol blue might have obscured the PCR product.  The annealing temperature 
chosen for PCR of each microsatellite marker is given in Appendix B.   
 
2.2.2.3 Amplification of Patient DNA 
Microsatellite markers were amplified in family members using the optimised PCR 
conditions (Appendix C).  A negative control, where distilled H2O (dH2O) replaced DNA, 
was included with PCRs set up to rule out contamination.  PCR cycling was carried out on 
either the Labnet MultiGene Thermal Cycler (Whitehead Scientific) or the Px2 Thermal 
Cycler (Thermo Electron Corporation) at the cycling conditions given in Appendix C and 
the annealing temperatures in Appendix B. 
 
2.2.3 Genotyping 
Genotyping of microsatellite markers was performed on the ABI Prism
®
 3100 Genetic 
Analyzer (Applied Biosystems) (Appendix C) in the Division of Human Genetics, UCT 












Set one was genotyped in two multiplexes and a single multiplex was sufficient for set 
two.   
 
Two-point Linkage Analysis, to test each microsatellite marker for linkage to ARVC, was 
performed using the LINKAGE program (version 5.10). 
 
2.3 Results 
Microsatellite marker genotypes for each family member are shown in Figure 2-1 to 
Figure 2-6.  The lod scores for six recombination fractions (θ) are provided in Table 2-2 to 
Table 2-7.  A lod score (Z) of 3.0 is the threshold for accepting linkage.  Linkage can be 
rejected if Z < -2.0 and values of Z between -2 and +3 are inconclusive (Strachan and 
Read, 2004a).  The recombination fraction is a measure of the genetic distance between 













Figure 2-1: Pedigree of ACM 2 showing genotypes for the ARVC-7 locus.  Microsatellite marker 
names are shown at the left of each generation.  Genotypes in brackets are inferred. 
 
Table 2-2: Two-point lod scores obtained for microsatellite markers in the ARVC-7 locus. 
  Lod score 
Marker Chromosomal  
position  
(in bp) 
θ = 0  θ = 0.1 θ = 0.2 θ = 0.3 θ = 0.4 θ = 0.5 
D10S1752 78,331,531 - 
78,331,811  
0.01 0.01 0 0 0 0 





0.13 0.20 0.13 0.03 0 
D10S201 81,029,072 - 
81,029,271  
0 0 0 0 0 0 
 
Haplotype 334 (represented in blue) is prominent in this family.  It is present in five affected family 
members (II:4, II:8, III:6, III:8 and III:9).  It is however not present in two affected family members 
(III:5 and III:12) and it is present in three unaffected family members (III:1, III:11 and IV:1).  This 
haplotype is therefore not tracking with disease in the family.  The lod score for D10S2327 at 













Figure 2-2: Pedigree of ACM 2 showing genotypes for the desmoplakin gene.  Microsatellite 
marker names are shown at the left of each generation.  Genotypes in brackets are inferred. 
 
Table 2-3: Two-point lod scores obtained for microsatellite markers within and flanking the 
desmoplakin gene. 
  Lod score 
Marker Chromosomal position  
(in bp) 
θ = 0  θ = 0.1 θ = 0.2 θ = 0.3 θ = 0.4 θ = 0.5 
D6S1547 7,514,077 - 7,514,371  0.27 0.11 -0.03 -0.11 -0.10 0 
DSP-M1 7,554,215 - 7,554,454 
(in intron 1 of gene) 
-4.14 -1.32 -0.80 -0.53 -0.30 0 
DSP-M2 7,800,154 - 7,800,382 -0.86 -0.46 -0.47 -0.45 -0.29 0 
 
Desmoplakin was excluded as a candidate gene as no haplotype is tracking with disease and a lod 



















Figure 2-3: Pedigree of ACM 2 showing genotypes for the plakophilin-2 gene.  Microsatellite 
marker names are shown at the left of each generation.  Genotypes in brackets are inferred. 
 
Table 2-4: Two-point lod scores obtained for microsatellite markers within and flanking the 
plakophilin-2 gene. 
  Lod score 
Marker Chromosomal position  
(in bp) 
θ = 0  θ = 0.1 θ = 0.2 θ = 0.3 θ = 0.4 θ = 0.5 
PKP2-M1 33,085,390 - 33,085,570 0.02 -0.03 0.19 0.25 0.18 0 
D12S1692 32,987,723 - 32,987,971 
(in intron 7 of gene) 
1.05 1.32 1.12 0.79 0.39 0 
PKP2-M2 32,849,128 - 32,849,468 0.77 0.66 0.51 0.35 0.17 0 
 
Haplotype 473 (represented in red) is present in all the affected family members genotyped except 
for family member III:5.  It is therefore unlikely that plakophilin-2 is the disease-causing gene in 
















Figure 2-4: Pedigree of ACM 2 showing genotypes for the desmoglein-2 gene.  Microsatellite 
marker names are shown at the left of each generation.  Genotypes in brackets are inferred.  The 
maternal allele is not indicated for family member III:5 as it is not possible to determine. 
 




It was not possible to determine which allele was inherited from which parent for family member 
II:4 and II:8.  Despite this it was still possible to exclude desmoglein-2 as a candidate gene as no 








  Lod score 
Marker Chromosomal position  
(in bp) 
θ = 0  θ = 0.1 θ = 0.2 θ = 0.3 θ = 0.4 θ = 0.5 













Figure 2-5: Pedigree of ACM 2 showing genotypes for the desmocollin-2 gene.  Microsatellite 
marker names are shown at the left of each generation.  Genotypes in brackets are inferred.  
Microsatellite marker AFM344ZD5 is not polymorphic in this family and therefore is not shown in 
the pedigree.  The maternal allele is not indicated for family members III:1 and III:5 as it is not 
possible to determine. 
 
Table 2-6: Two-point lod scores obtained for microsatellite markers flanking and within the 
desmocollin-2 gene. 
  Lod score 
Marker Chromosomal position  
(in bp) 
θ = 0  θ = 0.1 θ = 0.2 θ = 0.3 θ = 0.4 θ = 0.5 
DSC2-M1 28,717,808 - 28,718,093 -1.94 -0.74 -0.31 -0.10 -0.01 0 
DSC2-M2 28,653,147 - 28,653,437 
(in intron 12 of gene) 
-3.38 -1.44 -0.72 -0.32 -0.10 0 
 
Haplotype 43 (represented in blue) is prominent in this family but it is not tracking with disease.  
The lod score for DSC2-M2 (which lies within the gene) at θ = 0 is less than -2 which excludes 
















2.3.6 Plakoglobin  
Figure 2-6: Pedigree of ACM 2 showing genotypes for the plakoglobin gene.  Microsatellite 
marker names are shown at the left of each generation.  Genotypes in brackets are inferred. 
 
 
Table 2-7: Two-point lod scores obtained for the microsatellite marker flanking the plakoglobin 
gene. 
  Lod score 
Marker Chromosomal position  
(in bp) 
θ = 0  θ = 0.1 θ = 0.2 θ = 0.3 θ = 0.4 θ = 0.5 
D17S846 39,893,185 - 39,893,409  -4.26 -1.69 -0.69 -0.22 -0.02 0 
 
Plakoglobin was excluded as a candidate gene as no genotype is tracking with disease and a lod 













It was considered prudent to perform exclusion mapping of the other known ARVC loci 
prior to positional candidate gene analysis of the ARVC-6 locus.  The reason for this 
cautious approach was based on the less than definitive evidence for linkage of family 
ACM 2 to the ARVC-6 locus (Matolweni et al., 2006).  Furthermore, erroneous linkage in 
ARVC has been known to occur.  The ARVC-4 locus (2q32.1-q32.3) was identified based 
on the cumulative lod score of three small, unrelated ARVC families (Rampazzo et al., 
1997).  In one of these families a causal mutation was subsequently found in the 
plakophilin-2 gene on chromosome 12p11 (Gerull et al., 2004). 
 
Exclusion mapping was performed in family ACM 2 at the ARVC-7 locus and for five 
ARVC disease genes.  A total of 14 microsatellite markers were genotyped.  Lod scores 
less than -2 were obtained for the ARVC-7 locus, desmoplakin, desmoglein-2, 
desmocollin-2 and plakoglobin.  The lod score values obtained for plakophilin-2 do not 
support linkage of this locus with disease in this family.  No haplotype or genotype (as is 
the case for desmoglein-2 and plakoglobin) segregated with ARVC in this family.  The 
ARVC-7 locus and the five genes were therefore excluded from causing disease in this 
family.   
 
Furthermore, an affected ACM 2 family member was included in a screen of South 
African ARVC patients for mutations in the five disease genes: plakophilin-2 (Watkins et 
al., 2009), desmoplakin (Fish, 2010), desmoglein-2, desmocollin-2 and plakoglobin (Mr 
Mzwandile Mbele, unpublished work).  No disease-causing mutations were identified in 
this family member; this complementary approach supports the findings of the exclusion 
mapping of these five genes for this family.   
 
Based on the findings of this study, the next step was positional candidate gene analysis of 
the ARVC-6 locus.  It was decided to first prioritise the genes in this locus, for mutation 















3 PRIORITISATION OF CANDIDATE GENES 
3.1 Introduction 
Genome-wide linkage and association studies identify many candidate disease genes for 
further analysis (Tiffin et al., 2009).  Subsequently, a number of bioinformatics tools have 
been developed to prioritise candidate disease genes for empirical research.  A 
bioinformatics tool, GeneSeeker, selected RMRP as disease gene for skeletal dysplasia and 
it was confirmed to cause disease in patients (Thiel et al., 2005).  Another bioinformatics 
tool, G2D, selected ten genes for asthma and atopy in a French Canadian population 
(Tremblay et al., 2008).  A single nucleotide polymorphism (SNP) in one of the selected 
genes, PTPRE, was found to have a protective association with allergic asthma in this 
population.  Bioinformatics tools have also been used in concert to prioritise candidate 
genes for type 2 diabetes (Tiffin et al., 2006), fetal alcohol syndrome (Lombard et al., 
2007), osteoporosis (Huang et al., 2008) and metabolic syndrome (Tiffin et al., 2008).  
The advantage of using several bioinformatics tools together is to overcome the limitations 
inherent in each approach.  It was therefore decided to use several existing bioinformatics 
tools to prioritise genes in the ARVC-6 locus for mutation screening.   
 
3.2 Methods 
3.2.1 Candidate gene list 
Ensembl Gene IDs, for the genes located between microsatellite markers D10S1707 and 
D10S1477, were downloaded from the Ensembl database using BioMart 
(http://www.ensembl.org/biomart/index.html).  The datasets used were Ensembl 41 and 
Homo sapiens genes (NCBI 36).  A total of 26 Ensembl Gene IDs were retrieved.  The 

















Figure 3-1: The physical map of the ARVC-6 locus, from microsatellite marker 
D10S1707 to D10S1477, captured from the Ensembl database. 
 
3.2.2 eVOC method 
This bioinformatics method uses eVOC anatomical ontology to combine text-mining of 
biomedical literature and data-mining of human gene expression data (Tiffin et al., 2005).   
 
eVOC anatomy terms are extracted from PubMed abstracts containing the disease name of 
interest.  The identified eVOC anatomy terms are ranked according to frequency of 
association with the disease name and frequency of annotation of genes with eVOC terms.  
n top-scoring eVOC anatomy terms are selected from the ranked list and compared with 
eVOC anatomy terms annotated to candidate disease genes.  m mismatched terms are 
allowed (method described in full in Tiffin et al. 2005).   
 
A total of 628 abstracts, containing the disease name “arrhythmogenic right ventricular 
cardiomyopathy” OR “arrhythmogenic right ventricular dysplasia”, were downloaded 
from PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) on the 28
th
 of November 2006.   
 
Dragon Disease Explorer (DDE, http://research.i2r.a-star.edu.sg/DRAGON/DE/) was used 
to extract eVOC ontology terms in the abstracts.  The frequency of association and 












A python script slurpee.py (written by Alan Powell) was used to download all the 
information for the candidate genes from the Ensembl database and create a local 
database. The python scripts real_disease_gene_finder.py and real_iterations.py 
(written by Dr Nicki Tiffin) were run on the local database.  Candidate genes that were 
annotated with at least three of the four top ranked eVOC anatomy terms (namely: “heart”, 
“cardiovascular|vascular”, “artery”, “blood|peripheral blood”) were selected as the most 
likely disease gene candidates (recommended by Tiffin et al. 2005).  
 
3.2.3 GeneSeeker 
GeneSeeker is a web-based tool (http://www.cmbi.ru.nl/GeneSeeker/) that gathers and 
combines positional data and expression/phenotypic data from eb-based databases (van 
Driel et al., 2003; van Driel et al., 2005).  The user specifies the “genetic location” and 
“expression location” for the disease of interest.  GeneSeeker searches human and mouse 
genetic localisation, gene expression and phenotypic databases as listed in Table 3-1 (van 
Driel et al., 2003).   
 
The results are given in four tables: 
1.  A list of human genes in the correct genetic region and matching the specified 
expression profile 
2.  A list of mouse genes matching the syntenic region(s) as well as the expression profile, 
but with no matching human gene name 
3.  A list of mouse genes found in the syntenic region, for which the homologous human 
gene is found to map outside the critical interval    
4.  A list of all the remaining human genes that are present in the genetic interval, but 


































 UniProt (Swiss-Prot, TrEMBL, etc.)  
(srs.bioasp.nl:4080) 
  GXD 
(www.informatics.jax.org) 
  MLC 
(www.informatics.jax.org) 
  TBASE 
(www.informatics.jax.org) 
(van Driel et al., 2005) 
 
The Ensembl database was used to determine the cytogenetic band on which the 
microsatellite markers reside.  Both microsatellite markers were found on cytogenetic 
band 10p13.  BioMart was used to check that all the genes (situated between the two 
microsatellite markers) are on 10p13.  Various expression locations were entered i.e. heart, 
heart & ventricles, heart & right ventricle, heart & ventricle, cardiac.  The python script 
hugo_to_ensembl_id.py (written by Dr Nicki Tiffin) was used to convert HUGO IDs 
(also known as HGNC symbols) to Ensembl Gene IDs. 
 
3.2.4 Disease Gene Prediction (DGP) 
Disease Gene Prediction (DGP, http://maine.ebi.ac.uk:8000/services/dgp) is a relational 
database that contains a probability score, of being involved in disease, for each gene 
present in Ensembl version 15.33.1.  Probability scores were calculated based on the fact 
that proteins involved in hereditary diseases tend to be long, conserved, phylogenetically 












The website only allows submission of one Ensembl Gene ID at a time.  A python script 
screenscraper_dgp.py (written by Dr Nicki Tiffin) was used to submit a list of Ensembl 
Gene IDs to the website.  All 26 Ensembl Gene IDs were submitted to the website. 
 
3.2.5 PROSPECTR   
PROSPECTR (PRiOrization by Sequence & PhylogEnetic features of CandidaTe 
Regions) is a web-based prioritisation method available at 
http://www.genetics.med.ed.ac.uk/prospectr/.  It assigns a score (between 0 and 1) to each 
gene present in Ensembl version 27.  The higher the score the higher the likelihood of 
involvement in disease (Adie et al., 2005).  Scores were calculated based on eleven 
sequence features found to differ significantly between Ensembl genes found in Online 
Mendelian Inheritance in Man (OMIM) and those not in OMIM.  These sequence features 
include signal peptide, mouse homolog % identity, length of 3’ UTR, number of exons, rat 
homolog % identity, worm homolog % identity, GC, CDS length, gene length, mouse 
homolog Ka, paralog % identity (Adie et al., 2005). 
 
The “score a single gene” option was chosen over the “score genomic region” as 
PROSPECTR is not maintained as was therefore using an out of date version of the 
Ensembl database i.e. version 27. 
 
3.2.6 SUSPECTS 
SUSPECTS (http://www.genetics.med.ed.ac.uk/suspects/) is a web-based server that 
prioritises positional candidate genes by combining annotation and sequence-based 
approaches (Adie et al., 2006).  Two inputs are needed: the positional candidate genes and 
the known disease genes for the disorder (referred to as the “match set”).  Each positional 
candidate gene is scored on four lines of evidence.  PROSPECTR scores the gene on 
eleven sequence-based features.  The gene is then scored on how well its Gene Ontology 
(GO) terms (Ashburner et al., 2000), InterPro domains (Hunter et al., 2009) and gene 
expression profile correlates with the match set.  Each score is weighted depending on the 
amount of information available for each line of evidence.  The four scores are combined 












and the top score of 100 indicates a perfect match between the candidate gene and all 
genes in the match set (Adie et al., 2006).   
 
A list of Ensembl Gene IDs were submitted to SUSPECTS instead of ranking genes 
between markers as SUSPECTS is not maintained as was therefore using an out of date 
version of the Ensembl database i.e. version v28.3.  Two different match sets were 
submitted.  
 
Match set 1: The five known ARVC genes that encode desmosomal proteins (DSP, PKP2, 
DSG2, JUP and DSC2)  
Match set 2: All known ARVC genes at time of analysis (DSP, PKP2, DSG2, JUP, DSC2, 
RyR2 and TGFβ3) 
 
3.2.7 G2D 
G2D (genes to diseases) is a web-based tool (http://www.ogic.ca/projects/g2d_2/) that 
prioritises genes in a region of interest using the disease phenotype, known genes or a 
second genomic region linked to the disease (Perez-Iratxeta et al., 2007).  In this study the 
candidate genes were prioritised using the disease phenotype and known genes.   
 
Disease phenotype: 
The input for this approach is the region of interest and the OMIM identifier for the 
disease (Perez-Iratxeta et al., 2007).  G2D prioritises the genes in the region of interest 
according to the description of the phenotype and its pre-computed associations to gene 
features as extracted from the literature and the Entrez Gene database. 
 
Known genes: 
This approach requires the region of interest and the Entrez Gene ID of one or several 
human or mouse genes that are already known or are suspected to be involved in the 
disease (Perez-Iratxeta et al., 2007).  G2D prioritises the genes in the region of interest 
according to their similarity to the known gene(s) as given by their GO annotations and 













At time of analysis, the G2D website was being upgraded therefore the corresponding 
author (Carolina Perez-Iratxeta) was contacted for a list of GO IDs and scores associated 
with OMIM identifier ARVD-6 (604401) and the five known ARVC genes that encode 
desmosomal proteins (DSP, PKP2, DSG2, JUP, DSC2).  The python script 
g2d_go_analysis.py (written by Dr Nicki Tiffin) used the supplied list of GO IDs and 
scores to score the candidate genes.  The final score for each candidate gene is the 
maximum mapped GO score. 
 
3.2.8 Endeavour 
Endeavour is freely available software (http://www.esat.kuleuven.be/endeavour) that 
prioritises candidate “test” genes based on their similarity to known “training” genes 
(Aerts et al., 2006).  Known genes are used to gather information about a disease or 
biological pathway from the following data sources:   
A: literature (abstracts in EntrezGene) 
B: functional annotation (Gene Ontology) 
C: microarray expression (Atlas gene expression) 
D: EST expression (EST data from Ensembl) 
E: protein domains (InterPro) 
F: protein-protein interactions (Biomolecular Interaction Network Database (BIND)) 
G: pathway membership (Kyoto Encyclopedia of Genes and Genomes (KEGG)) 
H: cis-regulatory modules (TOUCAN) 
I: transcriptional motifs (TRANSFAC) 
J: sequence similarity (BLAST) 
K: additional data sources can be added 
 
Candidate genes are then ranked based on their similarity with the training properties 
obtained from the data sources.  This results in one prioritised list for each data source.  
The ranking from each data source is fused into a single ranking and provides an overall 
prioritisation for each candidate gene.  
 
Ensembl Gene IDs for all known ARVC genes at time of analysis (DSP, PKP2, DSG2, 












3.2.9 Tissue expression 
Tissue expression data, from the GeneCards
®
 database (http://www.genecards.org), was 
used to further prioritise the positional candidate genes.  The tissue expression data is 
derived from three sources (GeneNote - expression arrays (Shmueli et al., 2003), UniGene 
- electronic Northern (Wheeler et al., 2003) and CGAP: SAGE (Lal et al., 1999)) and is 
represented in bar graphs.  The genes received a score out of three, indicating the number 
of sources that showed normalised intensity/counts greater than 10 in the heart.   
 
3.3 Results 
3.3.1 eVOC method 
Seven genes were selected by this method namely: NMT2, FAM107B, C10orf97, HSPA14, 
SUV39H2, DCLRE1C and RPP38. 
 
3.3.2 GeneSeeker 
NMT2 was the only gene selected by this method. 
 
3.3.3 DGP 
There was probability information for 15 of the 26 Ensembl Gene IDs submitted.  The 
results are given in Table 3-2 below.  The genes with a probability score greater than 0.5 





















Table 3-2: Probability scores obtained for 15 candidate genes 
Ensembl Gene ID  HGNC Symbol Probability 
ENSG00000065809  FAM107B 0.7243 
ENSG00000185267 ARMETL1 0.474215 
ENSG00000152455 SUV39H2  0.592058 
ENSG00000152457  DCLRE1C  0.700131 
ENSG00000152463 OLAH 0.385372 
ENSG00000176244 ACBD7  0.392126 
ENSG00000176236 C10orf111  0.307754 
ENSG00000152464 RPP38  0.415991 
ENSG00000152465 NMT2  0.354711 
ENSG00000148468 C10orf38 0.18093 
ENSG00000077943 ITGA8 0.669706 
ENSG00000148481 C10orf97  0.489021 
ENSG00000165983 PTER  0.53326 
ENSG00000165985 C1QL3 0.599321 
ENSG00000151474 FRMD4A 0.366396 
 
3.3.4 PROSPECTR 
There were scores for 14 of the 26 Ensembl Gene IDs submitted.  The results are given in 
Table 3-3 below.  The genes with a score greater than 0.5 (highlighted in yellow) were 






















Table 3-3: Scores obtained for 14 candidate genes 
Ensembl Gene ID  HGNC Symbol Score 
ENSG00000065809 FAM107B 0.42  
ENSG00000187522 HSPA14 0.47  
ENSG00000152455 SUV39H2 0.43  
ENSG00000152457 DCLRE1C 0.52 
ENSG00000152463 OLAH 0.33 
ENSG00000176244 ACBD7 0.54  
ENSG00000176236 C10orf111 0.15  
ENSG00000152464 RPP38 0.43  
ENSG00000152465 NMT2 0.52  
ENSG00000148468 C10orf38 0.36  
ENSG00000077943 ITGA8 0.60  
ENSG00000148481 C10orf97 0.44  
ENSG00000165983 PTER  0.52  
ENSG00000151474 FRMD4A 0.54  
 
3.3.5 SUSPECTS 
Eight genes were not found in the hsapiens database and therefore could not be scored.  
Minor differences in rank order were observed when match set 1 was used compared to 
match set 2.  The top 20% of genes scored were selected and are the same regardless of the 
match set used namely: ITGA8, C1QL3, PTER and C10orf97.  Only the score and order of 
these genes differed.   
 
3.3.6 G2D 
The results of prioritisation using the disease phenotype and known genes are given in Table 3-4 and  
Table 3-5 respectively.  All scored genes (highlighted in yellow) were selected as potential 






































Ensembl Gene ID  HGNC Symbol Score 
ENSG00000176244  ACBD7 0 
ENSG00000165983  PTER 3.19e-006 
ENSG00000204942  - 0 
ENSG00000197889  MEIG1 1.76e-005 
ENSG00000065809  FAM107B 0 
ENSG00000201083  - 0 
ENSG00000187522  HSPA14 2.3e-005 
ENSG00000185221  - 0 
ENSG00000148481  C10orf97 4.19e-006 
ENSG00000148468  C10orf38 0 
ENSG00000209435  - 0 
ENSG00000152455  SUV39H2 1.76e-005 
ENSG00000165985  C1QL3 1.25e-005 
ENSG00000185267  ARMETL1 0 
ENSG00000182531  - 0 
ENSG00000201766  - 0 
ENSG00000198508  - 0 
ENSG00000151474  FRMD4A 4.27e-005 
ENSG00000176236  C10orf111 4.61e-006 
ENSG00000077943  ITGA8 1.98e-005 
ENSG00000152465  NMT2 1.25e-005 
ENSG00000201260  - 0 
ENSG00000209429  - 0 
ENSG00000152463  OLAH 0 
ENSG00000152464  RPP38 1.76e-005 












Table 3-5: Scores obtained using known genes as input 
Ensembl Gene ID  HGNC Symbol Score 
ENSG00000176244  ACBD7 0 
ENSG00000165983  PTER 2.15233 
ENSG00000204942  - 0 
ENSG00000197889  MEIG1 2.13895 
ENSG00000065809  FAM107B 0 
ENSG00000201083  - 0 
ENSG00000187522  HSPA14 0 
ENSG00000185221  - 0 
ENSG00000148481  C10orf97 3.88469 
ENSG00000148468  C10orf38 0 
ENSG00000209435  - 0 
ENSG00000152455  SUV39H2 2.13895 
ENSG00000165985  C1QL3 2.13895 
ENSG00000185267  ARMETL1 0 
ENSG00000182531  - 0 
ENSG00000201766  - 0 
ENSG00000198508  - 0 
ENSG00000151474  FRMD4A 4.76297 
ENSG00000176236  C10orf111 1.52036 
ENSG00000077943  ITGA8 5.16595 
ENSG00000152465  NMT2 1.67061 
ENSG00000201260  - 0 
ENSG00000209429  - 0 
ENSG00000152463  OLAH 0 
ENSG00000152464  RPP38 2.13895 
ENSG00000152457  DCLRE1C 1.73049 
 
3.3.7 Endeavour 
The top 25% of genes scored were selected namely: DCLRE1C, ITGA8, PTER, C1QL3, 
C10orf97, FRMD4A and OLAH.   
 
3.3.8 Combined results for prioritisation methods 
The results for each prioritisation method is summarised in Table 3-6.  A gene scored 1 if 
it was prioritised by the method, 0 if it was not prioritised by the method and 0.5 if the 
method could not prioritise the gene due to lack of information.  The scores were totalled 













Table 3-6: Combined prioritisation of candidate genes 
Ensembl Gene ID HGNC Symbol 
eVOC 




known genes Endeavour Total 
ENSG00000152457 DCLRE1C 1 0 1 1 0 1 1 1 6 
ENSG00000077943 ITGA8 0 0 1 1 1 1 1 1 6 
ENSG00000165983 PTER 0 0 1 1 1 1 1 1 6 
ENSG00000165985 C1QL3 0 0 1 0.5 1 1 1 1 5.5 
ENSG00000152465 NMT2 1 1 0 1 0 1 1 0 5 
ENSG00000148481 C10orf97 1 0 0 0 1 1 1 1 5 
ENSG00000152455 SUV39H2 1 0 1 0 0 1 1 0 4 
ENSG00000151474 FRMD4A 0 0 0 1 0 1 1 1 4 
ENSG00000197889 MEIG1 0 0 0.5 0.5 0 1 1 0 3 
ENSG00000152464 RPP38 1 0 0 0 0 1 1 0 3 
ENSG00000187522 HSPA14 1 0 0.5 0 0 1 0 0 2.5 
ENSG00000065809 FAM107B 1 0 1 0 0 0 0 0 2 
ENSG00000176236 C10orf111 0 0 0 0 0 1 1 0 2 
ENSG00000201766 - 0 0 0.5 0.5 0.5 0 0 0 1.5 
ENSG00000182531 - 0 0 0.5 0.5 0.5 0 0 0 1.5 
ENSG00000185221 - 0 0 0.5 0.5 0.5 0 0 0 1.5 
ENSG00000209429 - 0 0 0.5 0.5 0.5 0 0 0 1.5 
ENSG00000201260 - 0 0 0.5 0.5 0.5 0 0 0 1.5 
ENSG00000209435 - 0 0 0.5 0.5 0.5 0 0 0 1.5 
ENSG00000204942 - 0 0 0.5 0.5 0.5 0 0 0 1.5 
ENSG00000201083 - 0 0 0.5 0.5 0.5 0 0 0 1.5 
ENSG00000198508 - 0 0 0.5 0.5 0 0 0 0 1 
ENSG00000152463 OLAH 0 0 0 0 0 0 0 1 1 
ENSG00000176244 ACBD7 0 0 0 1 0 0 0 0 1 
ENSG00000185267 ARMETL1 0 0 0 0.5 0 0 0 0 0.5 












3.3.9 Tissue expression 
Only eight genes were scored based on tissue expression data and their score is given in 
brackets: C10orf97 (3), HSPA14 (3), NMT2 (2), FAM107B (2), PTER (1), RPP38 (1), 
ARMETL1 (1) and C10orf38 (1).  These genes were moved to the top of the ranked list to 
give the final prioritised list shown in Table 3-7.  Tissue expression of ITGA8 and 
FRMD4A was not investigated and they were excluded from the final prioritised list as 
they were screened for mutations previously (Matolweni et al., 2006).  The 16 genes 
without a score have normalised intensity/counts below 10 in the heart, are not expressed 



































Table 3-7: Final prioritisation of candidate genes   




























Note: genes highlighted in red = high expression in the heart 
















A total of 26 Ensembl Gene IDs were downloaded from the Ensembl database, between 
microsatellite markers D10S1707 and D10S1477, using BioMart.  Several existing 
bioinformatics tools and tissue expression data were used to prioritise the positional 
candidate genes for mutation screening.   
 
The reason for using several bioinformatics tools was to overcome the limitations inherent 
in each approach.  The utility of using bioinformatics tools in concert was extensively 
examined by Tiffin and colleagues (Tiffin et al., 2006).  Methods that rely on annotation 
and biomedical literature (e.g. the eVOC method, GeneSeeker and G2D) are potentially 
biased towards selecting better studied genes.  DGP and PROSPECTR score genes 
according to sequence features found to differ significantly between “disease genes” and 
“non-disease genes”.  While this approach is useful for identifying novel disease genes, 
genes that have been classified as “non-disease genes” might be found to cause disease in 
the future.  Some methods require input of known disease genes to prioritise candidate 
genes (e.g. SUSPECTS, G2D and Endeavour).  This approach is logical but restricts 
results to what is already known about the disease.  
 
Subsequent to this study, a list of positional candidate genes was downloaded from NCBI 
(http://www.ncbi.nlm.nih.gov/) (21 genes) and was compared to the list downloaded from 
the Ensembl database (26 Ensembl gene IDs).  Seventeen Ensembl gene IDs had a HGNC 
symbol and were present in the NCBI list.  The remaining nine Ensembl gene IDs did not 
have a HGNC symbol and none matched the 3 pseudogenes and hypothetical protein 
remaining in the NCBI list.  These nine Ensembl gene IDs genes were therefore removed 
from the final prioritised list. 
 
ITGA8 and FRMD4A were previously prioritised for mutation screening by Matolweni and 
colleagues because they were found to have cell-to-cell adhesion properties and five of the 
ARVC disease genes are involved in cell-to-cell adhesion (Matolweni et al., 2006).  In this 
study, ITGA8 and FRMD4A were prioritised second and eighth respectively in the ranked 
list (Table 3-6).  No disease-causing mutations were however identified in these two genes 
(Matolweni et al., 2006) and they were therefore not included in the final prioritised list 












4 MUTATION SCREENING 
4.1 Introduction  
The aim of this study was to screen the coding regions and intron-exon boundaries of 15 
genes in order of the final prioritised list (Chapter 3).  
 
4.2 Methods 
4.2.1 Mutation Screening by Sequencing  
Eight genes were screened for mutations by sequencing namely: C10orf97, HSPA14, 
NMT2, FAM107B, MEIG1, C10orf111, OLAH and ACBD7.   
 
4.2.1.1 PCR  
4.2.1.1.1 Primer Design 
Primers were designed for all the exons of the eight genes.  According to NCBI, OLAH 
has two isoforms.  Primers were therefore designed to screen the exons of both isoforms.    
An annotation program ANNOTV9 (designed by Dr George Rebello) was used to 
designate the exons and reported SNPs in the genome sequence.  Primer 3 was used to 
design the primers.  OligoAnalyzer 3.0 and BLAST (Basic Local Alignment Search Tool) 
were used to evaluate the primers for C10orf97.   
 
OligoAnalyzer 3.0 
(http://scitools.idtdna.com/scitools/Applications/OligoAnalyzer/Default.aspx) was used to 
identify possible: 
1. Hairpin structures: annealing of the primer with itself 
2. Homo-dimers: annealing of primers of the same type 












OligoAnalyzer 3.0 produces a graphical representation and a delta g value for each 
possible secondary structure of a primer.  An example of each secondary structure is given 
in Figure 4-1.  If the delta g value was -9kcal/mole or more negative, the primer was 
redesigned (OligoAnalyzer 3.0 technical support, personal communication). 
 
BLAST (http://blast.ncbi.nlm.nih.gov/) was used to search for the primer in the human 
genome.  If the 3’ end of the primer was found anywhere else in the genome, the primer 
was redesigned.   
 
In order to save time, reverse e-PCR was used to evaluate the remaining primers instead of 
OligoAnalyzer 3.0 and BLAST.  Reverse e-PCR was used to search for the primer pair in 
the human genome.  If the primer pair was found anywhere else in the genome, the 
primers were redesigned.  The sequence of these primers (Department of Molecular and 


















































Figure 4-1: Secondary structure prediction by OligoAnalyzer 3.0. A. Hairpin structure    












4.2.1.1.2 PCR Optimisation 
PCR was optimised using the temperature gradient function on the Labnet MultiGene 
Thermal Cycler (Whitehead Scientific) (Appendix C).  The PCR products were separated 
by gel electrophoresis through a 1% agarose gel and visualised using ethidium bromide 
(Appendix D).  A volume of 5µl of PCR product was mixed with 3µl agarose loading dye 
(Appendix E) and electrophoresed alongside a DNA ladder (0.5µg 1 Kb Plus DNA Ladder 
(Invitrogen, Laboratory Specialist Services), 0.5µg DNA Molecular Weight Marker XIV 
(Roche) or 650ng 100bp DNA Ladder (Promega, Whitehead Scientific) (Appendix F)).  
The annealing temperature chosen for PCR of each exon is given in Appendix B.   
 
4.2.1.1.3 Amplification of Patient DNA 
Exons were amplified in two affected and two unaffected family members using the 
optimised PCR conditions (Appendix C).  A negative control, where dH2O replaced DNA, 
was included with PCRs set up to rule out contamination.  PCR cycling was carried out on 
a Labnet MultiGene Thermal Cycler (Whitehead Scientific) at the cycling conditions 
given in Appendix C and the annealing temperatures in Appendix B. 
 
To confirm amplification, PCR products were separated by gel electrophoresis through a 
1% agarose gel and visualised using ethidium bromide (Appendix D).  A volume of 5µl of 
PCR product was mixed with 3µl agarose loading dye (Appendix E) and electrophoresed 
alongside a DNA ladder (0.5µg 1 Kb Plus DNA Ladder (Invitrogen, Laboratory Specialist 
Services), 0.5µg DNA Molecular Weight Marker XIV (Roche) or 650ng 100bp DNA 
Ladder (Promega, Whitehead Scientific) (Appendix F)). 
 
4.2.1.2 Sequencing   
Purification of PCR products was performed in 0.2ml tubes (Whitehead Scientific) in a 
total of 20µl containing 5 or 10µl of PCR product, 1 unit of Shrimp Alkaline Phosphatase 
(SAP) (Promega, Whitehead Scientific), 2 units of Exonuclease I (Exo I) (New England 
Biolabs, Laboratory Specialist Services) made up with dH2O.  Exo I removes the leftover 












MultiGene Thermal Cycler (Whitehead Scientific) for 60 minutes at 37
o
C to degrade the 
remaining primers and dNTPs followed by 15 minutes at 75
o
C to inactivate the enzymes.  
Primers were diluted to 1.1ng/µl and sent with the purified PCR products to the Central 
Analytical Facility, Stellenbosch University for sequencing.  Sequencing was performed in 
both directions to screen for mutations in the exons.   
 
The electropherograms were analysed by eye to identify heterozygous variants.  To 
identify homozygous variants, the patients’ sequences were aligned to the wild type 
sequence.  BioEdit version 7.0.0 (http://www.mbio.ncsu.edu/bioedit/bioedit.html) was 
used to align the sequences and the wild type sequence was obtained from NCBI. 
 
4.2.2 Mutation Screening by High Resolution Melt (HRM) 





Celtic Molecular Diagnostics), was used to screen for mutations in NMT2 exon 1.  This 
exon is 71% GC-rich and was difficult to sequence.  
 
4.2.2.1 Principle of HRM  
HRM analysis characterises DNA sequences based on their dissociation (melt) profiles.  
The DNA sequence is amplified by PCR in the presence of a double stranded DNA 
(dsDNA) intercalating fluorescent dye (e.g. EvaGreen
TM
).  The dye intercalates with 
dsDNA and fluoresces brightly.  The PCR products are subjected to a melt step and they 
transition from dsDNA to single stranded DNA (ssDNA) with increasing temperature.  
The dye is released and the fluorescence decreases. The Rotor-Gene
TM 
6000 collects the 
fluorescent signals.  Figure 4-2 shows a typical HRM plot.  The melt behaviour of a 
sequence depends on its composition and length (HRM Assay Design and Analysis 














(HRM Assay Design and Analysis booklet) 
Figure 4-2: A typical HRM plot. 
 
4.2.2.2 Primer Design  
Two extra primers were designed to divide the NMT2 exon 1 amplicon into two 
overlapping amplicons (NMT2 exon 1 amplicon 1 and 2).  OligoAnalyzer 3.0 and BLAST 
were used to evaluate the primers.  The sequence of primers NMT2Exon1F2 & R2 
(Whitehead Scientific) are given in Appendix B.   
 
4.2.2.3 PCR and HRM Optimisation 




(Corbett Research, Celtic Molecular Diagnostics) using two control DNA samples 
for each amplicon (Appendix C).  A suitable profile was not obtained for NMT2 exon 1 
amplicon 1 so this amplicon was screened for mutations by sequencing (Appendix C). 
 
4.2.2.4 Mutation Screening of Patients 
NMT2 exon 1 amplicon 2 was amplified in two affected and two unaffected family 
members using the optimised PCR and HRM conditions (Appendix C).  A positive control 
(one of the control DNA samples used in optimisation) and a negative control (dH2O 












4.2.3 Mutation Screening by Denaturing High Performance 
Liquid Chromatography (DHPLC) 
Seven genes were screened for mutations by DHPLC namely: PTER, RPP38, ARMETL1, 
C10orf38, DCLRE1C, C1QL3 and SUV39H2.   
 
4.2.3.1 PCR 
4.2.3.1.1 Primer Design 
Primers were designed for all the exons of the seven genes.  According to NCBI, PTER 
and RPP38 both have two isoforms.  Primers were therefore designed to screen the exons 
of both isoforms.  ANNOTV9 was used to annotate the genome sequence with exons and 
SNPs, Primer 3 was used to design the primers and reverse e-PCR was used to evaluate 
the primers.  The sequence of these primers (Invitrogen, Italy) is given in Appendix B. 
 
4.2.3.1.2 PCR Optimisation 
PCR was optimised using the temperature gradient function on the Mastercycler® pro 
(Eppendorf) (Appendix C).  The PCR products were separated by gel electrophoresis 
through a 2% agarose gel and visualised using ethidium bromide (Appendix D).  A 
volume of 5µl of PCR product was mixed with 1µl ReddyRunTM gel loading buffer 
(ABgene) and electrophoresed alongside either 0.15µg Superladder-Low 100bp Ladder 
with ReddyRun
TM
 (ABgene) or 0.3µg 100bp DNA Ladder (GENECRAFT) (Appendix F).  
The annealing temperature chosen for PCR of each exon is given in Appendix B.    
 
4.2.3.1.3 Amplification of Patient DNA  
Exons were amplified in duplicate in a positive control (the control DNA sample used in 
optimisation), two affected and two unaffected family members using the optimised PCR 
conditions (Appendix C).  A negative control, where dH2O replaced DNA, was included 
with PCRs set up and run on the WAVE machine to rule out contamination.  PCR cycling 
was carried out on the Mastercycler® pro (Eppendorf) at the cycling conditions given in 













DHPLC, performed by the WAVE
R
 System (Transgenomic), was used to screen for 
mutations in the exons.  This method was initially developed in 1995 by Oefner and 
Underhill (Oefner and Underhill, 1995).   
 
4.2.3.2.1 Principle of DHPLC 
DHPLC, under partial denaturing conditions, can detect single base substitutions, small 
insertions and deletions (Xiao and Oefner, 2001).  Prior to DHPLC analysis, PCR products 
are denatured at 95
o
C for 5 minutes and re-annealed by gradual cooling.  If one of the 
chromosomes contains a sequence variant, the PCR products will re-anneal to form the 
original homoduplexes and the sense and anti-sense stands from different PCR products 
will form heteroduplexes (Xiao and Oefner, 2001).   
 
The PCR products are loaded on the WAVE machine which injects the sample onto the 
separation cartridge.  The cartridge is filled with alkylated nonporous polystyrene-
divinylbenzene (PS-DVB) beads which are electrostatically neutral and hydrophobic.  To 
aid adsorption of nucleic acids to the beads, triethylammonium acetate (TEAA) is added.  
This reagent is positively charged and hydrophobic therefore it interacts with nucleic acids 
(which are negatively charged) and the hydrophobic beads.  Increasing concentrations of 
acetronitrile flows across the cartridge.  The hydrophobic interaction between the cartridge 
and DNA/TEAA is broken and the PCR product elutes (WAVE
R
 manual).  Under partial 
denaturing co ditions, heteroduplexes denature more extensively at the analysis 
temperature and therefore elute earlier than the homoduplexes that undergo less 
pronounced denaturation.  The ideal chromatographic profile is illustrated in Figure 4-3.  
The order of elution of the four species is primarily determined by neighbouring stacking 


























(Xiao and Oefner, 2001) 
Figure 4-3:  An ideal chromatographic profile for a mismatch. 
 
4.2.3.2.2 Design of WAVE methods 
A WAVE method consists of an analysis temperature and DHPLC conditions. 
WAVEMAKER
TM
 software was used to identify the melting domains in an amplicon and 
a WAVE method was designed for each domain.  The analysis temperature for a domain 
was chosen where the helical fraction (i.e., double strandedness) of the domain is between 
75 - 100%.  The application type “mutation detection” was selected. 
 
The WAVE methods were tested on the control sample that amplified the best during PCR 
optimisation.  A volume of 10µl of PCR product was injected onto the cartridge for each 
WAVE method.  The temperatures were adjusted or fewer temperatures were used based 
on the test run.  Suitable chromatographic profiles were not obtained for RPP38 exon 2 so 












4.2.3.2.3 Mutation Screening of Patients 
 Heteroduplex formation was carried out on the Mastercycler® pro (Eppendorf).  The 
samples were denatured at 95
o
C for 5 minutes and then the temperature was decreased by 
1
o




C.  The samples then stood for 10 minutes at room 
temperature.   
 
4.2.3.3 Sequencing 
All amplicons with aberrant chromatographic profiles were sequenced in both directions 
(Appendix C).   
 
4.3 Results  
A total of 36 sequence variants (SVs) were identified in the 15 genes.  Twenty-nine SVs 
have been reported as SNPs on the NCBI SNP database and seven SVs are novel.  Only 
one SV, c.1641A>G in DCLRE1C, was found in the two affected family members and 
was not present in the two unaffected family members screened.  This single base 
substitution results in a synonymous amino acid change.  A summary of the SVs is given 























Table 4-1: A summary of the sequence variants identified 
HGNC 
Symbol 






C10orf97 NM_024948.2 c.-5T>C rs2297882 Noncoding 
C10orf97 NM_024948.2 c.731-23G>T - Noncoding 
C10orf97 NM_024948.2 c.956-90G>A - Noncoding 
HSPA14 NM_016299.2 c.-8G>T - Noncoding 
HSPA14 NM_016299.2 c.-7C>T - Noncoding 
NMT2 NM_004808.2 c.1170+68T>G rs10906832 Noncoding 
NMT2 NM_004808.2 c.1171-12T>C rs7072269 Noncoding 
NMT2 NM_004808.2 c.1339-69A>C rs7918775 Noncoding 




































ARMETL1 NM_001029954.2 c.306A>C rs61843027 Synonymous 
(P>P) 
C10orf38 NM_001010924.1 c.418+19delT - Noncoding 
C10orf38 NM_001010924.1 c.1393C>T rs3814165 Missense (P>S) 













MEIG1 NM_001080836.2 c.-29-307A>G rs6602774 Noncoding 
MEIG1 NM_001080836.2 c.-29-216T>C rs4750567 Noncoding 
MEIG1 NM_001080836.2 c.-29-132T>C rs4237442 Noncoding 
MEIG1 NM_001080836.2 c.26A>C rs4750568 Missense (K>T) 
MEIG1 NM_001080836.2 c.139-94C>G rs1935400 Noncoding 
MEIG1 NM_001080836.2 c.139-72A>G rs1935399 Noncoding 
MEIG1 NM_001080836.2 c.*58C>T rs4418687 Noncoding 
MEIG1 NM_001080836.2 c.*62A>G rs4295952 Noncoding 
MEIG1 NM_001080836.2 c.*204T>C rs5019235 Noncoding 
MEIG1 NT_008705.16 g.14954935A>G rs11259410 Noncoding 
MEIG1 NT_008705.16 g.14954964A>C rs11259411 Noncoding 
C10orf111 NM_153244.1 c.209G>A rs7896053 Missense (R>K) 







ACBD7 NM_001039844.2 c.12+41G>A rs12261006 Noncoding 
ACBD7 NM_001039844.2 c.130+58G>A rs4750594 Noncoding 
 
Note: The SV found exclusively in the two affected family members screened is written in 
bold. 
 
4.4 Discussion  
A comprehensive mutation screening study was conducted for 15 genes in the ARVC-6 
region using different methods.  The top four prioritised genes (C10orf97, HSPA14, NMT2 
and FAM107B) were considered important candidate genes due to their high expression in 
the heart.  These genes were therefore screened using a definitive method of mutation 
detection i.e. sequencing.  NMT2 exon 1 was problematic to sequence due to its high GC 
content.  Two extra primers were designed to divide the NMT2 exon 1 amplicon into two 
overlapping amplicons (NMT2 exon 1 amplicon 1 and 2).  NMT2 exon 1 amplicon 1 was 
screened by sequencing and NMT2 exon 1 amplicon 2 was screened by HRM.  The next 
seven genes on the prioritised list (PTER, RPP38, ARMETL1, C10orf38, DCLRE1C, 












rapid and nearly 100% of sequence variations can be detected (Oefner and Underhill, 
1999; Xiao and Oefner, 2001).  The remaining four genes (MEIG1, C10orf111, OLAH and 
ACBD7) had few, small exons and were therefore screened for mutations by sequencing.   
 
A total of 36 SVs were identified.  Twenty-nine SVs have been reported as SNPs on the 
NCBI SNP database and seven SVs are novel.  Only one SV, c.1641A>G in DCLRE1C, 
was found in the two affected family members and was not present in the two unaffected 
family members screened.  This substitution results in a new codon but it specifies the 
same amino acid (i.e. synonymous substitution).     
 
Some synonymous substitutions have been found to affect pre-mRNA splicing (Cartegni 
et al., 2002).  Incorrect splicing creates aberrant mRNAs that are either unstable or code 
for defective or deleterious protein isoforms.  In ARVC, a homozygous synonymous 
substitution was identified in PKP2 that causes cryptic splicing (Awad et al., 2006).  In 
this study, it is therefore important to screen the synonymous substitution found in 
DCLRE1C in the rest of family ACM 2.  If the SV is found to track with disease in the 
family then its effect on pre-mRNA splicing will need to be experimentally determined. 
 
While no overt disease-causing mutations were identified in the coding regions and intron-
exon boundaries, mutations in the 5’ and 3’ UTRs cannot be ruled out.  Beffagna and 
colleagues reported disease-causing mutations in the 5’ and 3’ UTRs of the TGFβ3 gene 
(Beffagna et al., 2005).  In a canine model of ARVC, dogs homozygous for an 8bp 
deletion in the 3’ UTR of the striatin gene had a more severe form of disease (Meurs et al., 
2010).   
 
Two positional candidate genes, PTPLA (Li et al., 2000b) and Human NAPOR (CUGBP2) 
(Li et al., 2001), were screened in the North American family in which the ARVC-6 locus 
was originally mapped (Li et al., 2000a).  No disease-causing mutations were identified.  
These two genes are not in the linkage region of family ACM 2 and therefore were not 













The mutation screening methods employed in this study (i.e. sequencing, HRM and 
DHPLC) would not have identified copy-number variations (CNVs).  It was therefore 






































5 MUTATION SCREENING FOR COPY-
NUMBER VARIANTS 
5.1 Introduction 
A copy-number variation (CNV) is a segment of DNA that represents an imbalance 
between two genomes from one species (Stankiewicz and Lupski, 2010).  Deletions, 
duplications, triplications, insertions or translocations can result in CNVs.  This structural 
variation has been implicated in Mendelian diseases (e.g. Duchenne muscular dystrophy), 
common complex traits (e.g. autism) and disease susceptibility (e.g. psoriasis). 
  
It was decided to screen for CNVs in the ARVC-6 region using the Affymetrix
®
 Genome-
Wide Human SNP Array 6.0 (hereafter referred to as SNP Array 6.0).  The SNP Array 6.0 
contains 906,600 single nucleotide polymorphisms (SNPs) and 946,000 non-polymorphic 
probes for the detection of copy-number variation with a combined intermarker genome 
spacing of 680 bases (Affymetrix
®






5.2.1 SNP Array 6.0  
A DNA sample from one affected family member (III:9 sample C) was sent to the Centre 
for Proteomic and Genomic Research (CPGR), University of Cape Town for genotyping 
with the SNP Array 6.0.  Family member III:9 was one of the affected family members 
screened for mutations in Chapter 4.  DNA sample C had sufficient quantity and quality of 
DNA.  This specific sample was also genotyped for exclusion mapping and sample mix up 
can therefore be ruled out.   
 
The CPGR determined the concentration and assessed the integrity of the DNA sample.  
The DNA was diluted to a working concentration of 50ng/µl and the Affymetrix® 
Genome-Wide Human SNP Assay 5.0/6.0 protocol was followed.  A total of 500ng DNA 












ligated DNA fragments 200 to 1,100bp in size were preferentially amplified using 
optimised PCR conditions and a primer that recognises the adaptor sequence.  The PCR 
products, for each restriction enzyme digest, were combined and purified using 
polystyrene beads.  The amplified DNA was fragmented, labelled with biotin and 
hybridised to the SNP Array 6.0 (Affymetrix
®
 Genome-Wide Human SNP Array 6.0 Data 
Sheet).  The array was rinsed to remove DNA that did not bind.  A fluorescent stain was 
added and the fluorescent molecules adhered to the biotin (Structure & Function of 
GeneChip® Microarrays).  The results were generated by laser-guided optical scanning of 





 Genome-Wide Human SNP Array 6.0 Data Sheet) 













5.2.2 Quality Control 
Quality control for the genotyping and copy-number analysis was performed by the CPGR 
using the Birdseed version 2 and Canary version 2 algorithms respectively on the 
Affymetrix Genotyping Console
®
 4.0.   
 
5.2.3 Copy-Number Analysis 
Copy-number analysis was performed by the CPGR using the Canary version 2 algorithm 
on the Affymetrix Genotyping Console
®
 4.0 and a reference model file provided by 
Affymetrix (GenomeWideSNP_6.hapmap270.na30.r1.a5.ref).  The following segment 
reporting parameters were used: minimum number of markers per segments: 5, minimum 
genomic size of segment: 0.1kb and include segments that overlap with known CNV: 
100%.   
 
Analysis was also performed changing the following Canary parameters sequentially:   
1. Transition Decay from 1000Mb to 10Mb 
2. CN Minimum Number Marker Threshold from 1 to 0 
3. Regional GC correction to no regional GC correction 
 
The default settings of these three parameters model the data to obtain the best fit 
regardless of experimental error and array inconsistencies.  The three parameters were 
changed sequentially to obtain the unmodelled data and possibly identify regions that were 
missed during the initial analysis. 
 
5.3 Results 
The sample had a contrast QC (quality control measure of genotyping analysis) of 2.49 
(Affymetrix recommended threshold should be greater than 1.7).  The sample had a 
median absolute pairwise difference (MAPD) (quality control measure of copy-number 
analysis) of 0.28 (Affymetrix recommended threshold should be less than 0.35).  The 













No CNV was found in the ARVC-6 region despite changing various parameters i.e. 
transition decay, CN minimum number marker threshold and selecting no regional GC 
correction. 
 
5.4 Discussion  
Copy-number analysis, of one affected family member, did not identify any CNVs in the 
ARVC-6 region.  Copy-number analysis was performed for the whole genome which is an 
unbiased approach to data analysis.  The results of only the ARVC-6 region were reported 
as this locus shows linkage in family ACM 2.  The Canary parameters were set to identify 
known, partially known and novel CNVs.    
 
A similar approach as this study was used to successfully identify the genetic cause of an 
autoinflammatory disease in a single patient (Reddy et al., 2009).  Genomewide copy-
number analysis was performed using a SNP Array 6.0, the Affymetrix Genotyping 
Console
®
 2.0 and a reference model (GenomeWideSNP_6.hapmap270.422 data set).  A 
175kb homozygous deletion at chromosome 2q13 was identified, in the patient, which 
encompasses six interleukin-1 family members.  The consanguineous parents were 
heterozygous for this deletion and were healthy. 
 
Since no CNVs were identified in the ARVC-6 region, two different approaches were 
considered as the next experiment: whole-genome genetic linkage analysis or sequencing 
the ARVC-6 region using next-generation sequencing (NGS). 
 
NGS are newer methods of sequencing compared to the automated Sanger method (“first-
generation”) (Metzker, 2010).  These newer methods are able to produce large volumes of 
sequence data cheaper than the Sanger method.  NGS is commercially available from 
Roche/454, Illumina/Solexa, Life/APG and Helicos BioSciences.  Each company employs 
different strategies for NGS but in general the steps involved are template preparation, 
sequencing & imaging and data analysis.  Sequencing the whole ARVC-6 region was 













In the end, whole-genome genetic linkage analysis was chosen as the next experiment.  
This approach was considered the sensible option as linkage to only the known ARVC loci 
was performed in family ACM 2 and the lod score obtained for the ARVC-6 locus (2.93) 


































6 WHOLE-GENOME SNP LINKAGE 
ANALYSIS 
6.1 Introduction 
SNP genotyping arrays have been shown to be more efficient and precise than genotyping 
microsatellite markers in genomewide linkage searches for Mendelian disease loci (Sellick 
et al., 2004).  It was therefore decided to genotype the whole-genome of ACM 2 family 
members using the Illumina
®
 HumanCytoSNP-12 BeadChip.  This BeadChip contains 
200,000 tag SNPs and 220,000 markers that target regions of known cytogenetic 
importance 
(http://www.illumina.com/products/humancytosnp_12_dna_analysis_beadchip_kits.ilmn).  
This experiment would refine the ARVC-6 region and may identify other disease-




A total of 14 DNA samples met the quality and quantity requirements for genotyping with 
the HumanCytoSNP-12 BeadChip.  Since this BeadChip genotypes 12 samples at the 
same time, it was decided to genotype DNA samples from family members: I:2, II:3, II:4, 
II:6, II:8, III:1, III:5, III:6, III:8, III:9, III:11, III:12 (5 unaffected and 7 affected family 
members).  The DNA samples were diluted to a working concentration of 50ng/µl and 
were sent to Xenon Pharmaceuticals Inc., Canada for genotyping on the BeadChip using 
the Infinium HD Assay Ultra (Infinium
®
 HD Assay Ultra Protocol Guide).  
 
The DNA samples were denatured, neutralised and isothermally amplified overnight.  The 
DNA was fragmented by a controlled enzymatic process that uses end-point fragmentation 
to avoid overfragmenting the sample.  The fragmented DNA underwent isopropanol 
precipitation and was subsequently collected by centrifugation at 4
o
C.  The precipitated 
DNA was resuspended in hybridisation buffer.  The BeadChip was prepared for 












BeadChip and divided by an IntelliHyb
® 
seal (or gasket).  The loaded BeadChip was 
incubated overnight in the Illumina Hybridization Oven.  During hybridisation the 
fragmented DNA samples annealed to locus-specific 50-mers covalently linked to the 
beads (see Figure 6-1A).  The BeadChip was washed to remove unhybridised and non-
specifically hybridised DNA.  The captured DNA was used as a template to extend the 
oligos on the beads by a single-base (see Figure 6-1B).  The Illumina iScan was used to 
scan the BeadChip.  The scanner used a laser to excite the fluorophore of the single-base 
extension product on the beads.  It then recorded high-resolution images of the light 
emitted from the fluorophores. 
 
                                          

















 HD Assay Ultra Protocol Guide) 
Figure 6-1: A. Fragmented DNA (gDNA) annealed to oligos covalently linked to a bead.              
B. Single-base extension of the oligos on a bead. 
 
6.2.2 Analysis  
Two point and multipoint linkage analyses were performed by Xenon Pharmaceuticals 












that implements the Lander-Green algorithm.  This program is particularly good for 
analysing whole-genome searches of modest sized pedigrees (Strachan and Read, 2004b) 
such as is the case in this study.  The program parameters were set to autosomal dominant 
inheritance with a penetrance of 0.90, phenocopy of 0.02 and a disease allele frequency of 
0.001.   
 
Xenon Pharmaceuticals Inc. also performed haplotype analysis using 18 informative SNPs 
on chromosome 4 to confirm the segregation of a susceptibility allele with ARVC in 
family ACM 2.   
 
6.3 Results 
6.3.1 Linkage analysis 
In the two-point linkage analysis lod scores above two were obtained on chromosome 1, 4, 
10 and 12.  Table 6-1 gives the SNP(s) with the highest two-point lod score on each of the 
four chromosomes.  In multipoint linkage analysis lod scores above two were obtained on 
chromosome 4 and 10.  Both regions had a peaking lod score of 2.79.  The chromosome 4 
-1lod interval is between pter and SNP rs13115900 which corresponds to an interval of 
~6.93 Mb.  The chromosome 10 -1lod interval is between SNPs rs7893899 and 
rs10795384 which corresponds to an interval of ~2.69 Mb.   
 
Table 6-1: SNPs with the highest lod scores in two-point linkage analysis 
Chromosome lod SNP 
1 2.73 rs10912216 
4 2.78 rs6810785 
rs34782960 
10 2.72 rs1155200 















6.3.2 Haplotype analysis  
In Figure 6-2 a truncated ACM 2 pedigree is shown along with the genotypes for 18 
informative SNPs on chromosome 4.  Affected individual III:6 has a recombination event 
between SNPs rs4689562 and rs10155062.  The chromosome 4 linkage interval is 
therefore between pter and SNP rs10155062 (~7.18Mb).  This is close to the -1lod interval 














Figure 6-2: Truncated pedigree of ACM 2, showing genotypes useful for delimiting crossover 
points on chromosome 4.  SNP names are shown at the left of each generation.  Genotypes for I:1, 
II:1, II:2 and II:7 (pedigree numbers in brackets) are inferred. Blue bars represent the disease-
associated haplotype and recombination events are marked with red lines.  Individual III:6 has a 
recombination that delimits the region. 
 
III:12 
II:3 II:4 II:6 (II:7) II:8 
















A peak multipoint lod score of 2.79 was obtained on chromosome 4 and 10.  The 
chromosome 10 -1lod interval is ~2.69Mb and correlates with the published two-point lod 
score of 2.93 and linkage interval of ~2.9Mb for this family (Matolweni et al., 2006).  
Haplotype analysis of the chromosome 4 region identified a linkage interval of ~7.18Mb.  
This linkage interval is not a known ARVC locus and was not previously linked to this 
family because linkage analysis was only performed on known ARVC loci.   
 
This is the first time to our knowledge that whole-genome SNP linkage analysis has been 
used to identify a new disease locus for ARVC.  The previous ARVC loci were identified 
by whole-genome genetic linkage analysis genotyping families with microsatellite markers 
or disease genes were identified by screening biologically plausible genes for mutations.   
 
High-density genome-wide SNP arrays have assisted in identifying the disease-causing 
mutation in a family with ARVC and another family with DCM (Van Der Zwaag et al., 
2010).  Van der Zwaag and colleagues hypothesised that the longest shared haplotype, 
among affected family members, is most likely to contain the disease-causing mutation.  
They state that “short haplotypes are common and either represent ancient identical-by-
descent (IBD) stretches of DNA or are identical-by-state (IBS)”.  The largest haplotype in 
the ARVC and DCM families contained known disease genes (PKP2 and MYH7 
respectively) and mutation screening indentified the disease-causing mutation.  Van der 
Zwaag and colleagues went on to calculate that a pedigree with at least seven meioses has 
a high chance of correctly detecting the mutation-containing haplotype as the largest.   
 
In family ACM 2, the linkage interval on chromosome 4 is the largest.  The linkage 
interval on chromosome 10 is probably shared due to hidden distant ancestry or IBS.  The 
chromosome 4 linkage interval is therefore another plausible locus for this family.  A total 
of 90 genes with a HGNC symbol were identified in this linkage interval using BioMart on 














7 DISCUSSION  
7.1 The aim of this project 
The aim of this project was to identify a novel disease gene that causes ARVC in a South 
African family of European descent (family ACM 2). 
 
7.2 Summary of work 
Linkage analysis of family ACM 2 was previously performed at six known ARVC loci 
(Matolweni et al., 2006).  ARVC loci 1 to 5 were excluded as disease loci in this family 
based on lack of evidence for linkage.  However, a peak lod score of 2.93 was obtained for 
the ARVC-6 locus which is highly suggestive of linkage.  When this project was started, 
another locus (ARVC-7) and five ARVC disease genes (i.e. desmoplakin, plakophilin-2, 
desmoglein-2, desmocollin-2 and plakoglobin) had since been reported.   
 
Exclusion mapping was performed in family ACM 2 at the ARVC-7 locus and for five 
ARVC disease genes.  Lod scores less than -2 were obtained for the ARVC-7 locus, 
desmoplakin, desmoglein-2, desm collin-2 and plakoglobin.  The lod score values 
obtained for plakophilin-2 do not support linkage of this locus with disease in this family.  
No haplotype or genotype (as is the case for desmoglein-2 and plakoglobin) segregated 
with ARVC in this family.  The ARVC-7 locus and the five genes were therefore excluded 
from causing disease in this family.   
 
Furthermore, an affected ACM 2 family member was included in a screen of South 
African ARVC patients for mutations in the five disease genes: plakophilin-2 (Watkins et 
al., 2009), desmoplakin (Fish, 2010), desmoglein-2, desmocollin-2 and plakoglobin (Mr 
Mzwandile Mbele, unpublished work).  No disease-causing mutations were identified in 
this family member; this complementary approach supports the findings of the exclusion 













Based on the findings of the exclusion mapping, the ARVC-6 locus was further 
investigated.  Several existing bioinformatics tools and tissue expression data were used to 
prioritise positional candidate genes in the ARVC-6 locus for mutation screening.   
 
Comprehensive mutation screening was conducted for 15 genes using different methods.  
A total of 36 sequence variants (SVs) were identified.  Twenty-nine SVs have been 
reported as SNPs on the NCBI SNP database and seven SVs are novel.  Only one SV, 
c.1641A>G in DCLRE1C, was found in the two affected family members and was not 
present in the two unaffected family members screened.  This substitution results in a new 
codon but it specifies the same amino acid (i.e. synonymous substitution).  The 
significance of this SV is unknown.   
 
While no overt disease-causing mutations were identified in the coding regions and intron-
exon boundaries, mutations in the 5’ and 3’ untranslated regions (UTRs) cannot be ruled 
out.  Beffagna and colleagues reported disease-causing mutations in the 5’ and 3’ UTRs of 
the TGFβ3 gene (Beffagna et al., 2005).  In a canine model of ARVC, dogs homozygous 
for an 8bp deletion in the 3’ UTR of the striatin gene had a more severe form of disease 
(Meurs et al., 2010).   
 
The mutation screening methods employed in this study (i.e. sequencing, High Resolution 
Melt (HRM) and Denaturing High Performance Liquid Chromatography (DHPLC)) would 
not have identified copy-number variations (CNVs).  Copy-number analysis, of one 
affected family member, was performed using an Affymetrix
®
 Genome-Wide Human SNP 
Array 6.0, the Affymetrix Genotyping Console
®
 4.0 and a reference model file provided 
by Affymetrix.  No CNV was found in the ARVC-6 region.  
 
Whole-genome SNP linkage analysis was performed in family ACM 2 to refine the 
ARVC-6 region and possibly identify other disease-associated regions.  A peak multipoint 
lod score of 2.79 was obtained on chromosome 4 and 10.  The chromosome 10 -1lod 
interval is ~2.69Mb and correlates with the published two-point lod score of 2.93 and 
linkage interval of ~2.9Mb for this family (Matolweni et al., 2006).  Haplotype analysis of 












is not a known ARVC locus and was not previously linked to this family because linkage 
analysis was only performed on known ARVC loci.   
 
This is the first time to our knowledge that whole-genome SNP linkage analysis has been 
used to identify a new disease locus for ARVC.  The previous ARVC loci were identified 
by whole-genome genetic linkage analysis genotyping families with microsatellite markers 
or disease genes were identified by screening biologically plausible genes for mutations.   
 
High-density genome-wide SNP arrays have assisted in identifying the disease-causing 
mutation in a family with ARVC and another family with DCM (Van Der Zwaag et al., 
2010).  Van der Zwaag and colleagues hypothesised that the longest shared haplotype, 
among affected family members, is most likely to contain the disease-causing mutation.  
They state that “short haplotypes are common and either represent ancient identical-by-
descent (IBD) stretches of DNA or are identical-by-state (IBS)”.  The largest haplotype in 
the ARVC and DCM families contained known disease genes (PKP2 and MYH7 
respectively) and mutation screening indentified the disease-causing mutation.  Van der 
Zwaag and colleagues went on to calculate that a pedigree with at least seven meioses has 
a high chance of correctly detecting the mutation-containing haplotype as the largest.   
 
In family ACM 2, the linkage interval on chromosome 4 is the largest.  The linkage 
interval on chromosome 10 is probably shared due to hidden distant ancestry or IBS.  The 
chromosome 4 linkage interval is therefore another plausible locus for this family.   
 
7.3 Future work 
It is important to screen the synonynous substitution found in DCLRE1C in the rest of the 
ACM 2 family.  If the SV is found to track with disease in the family then its effect on pre-
mRNA splicing will need to be experimentally determined. 
 
A total of 90 genes with a HGNC symbol were identified in the chromosome 4 linkage 
interval using BioMart on the Ensembl database.  These genes could be prioritised and 
screened for mutations or the whole linkage interval could be sequenced using next-
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Appendix B: Primers  







Max Het. Type of 
repeat 












0.6700 CA D10S1752_F tactgtcctctatttcatttctaca 275-285 FAM a 
    D10S1752_R 
 
aatttattacaagcaaaaccaccct  -  
 D10S2327 
 
no info GGAT D10S2327_F 
 
cccagagcaagtactcacct 200-228 FAM 52 
    D10S2327_R 
 
atagttttgtgcttattgacatga  -  
 D10S201 
 
0.8331 CA D10S201_F 
 
ggcatggtttgaggatgagaggg 210 HEX 49 
    D10S201_R 
 





0.6606 CA D6S1547_F 
 
ccttgagcaccttaaattttt 290-304 HEX a 
    D6S1547_R 
 





0.8349 CA D12S1692_F 
 
ctttgattccataccctcct 245-261 HEX a 
    D12S1692_R 
 





0.7500 CA D18S36_F 
 












    D18S36_R 
 





no info CA AFM344ZD5_F 
 
gttttagtgcctgtgcc 132 FAM 52 
    AFM344ZD5_R 
 






0.8290 GGAA D17S846_F 
 
tgcatacctgtactacttcag 215 FAM a 
    D17S846_R 
 
tcctttgttgcagatttcttc  -  
Note: DSP = Desmoplakin; PKP2 = Plakophilin-2; DSG2 = Desmoglein-2; DSC2 = Desmocollin-2; JUP = Plakoglobin; Max Het. = Maximum 
Heterozygosity (from The Genome Database http://www.gdb.org); F = forward primer; R = reverse primer; PCR product sizes from 

































Type of repeat Name of primer Primer sequence (5’-3’) PCR product 
size 
(in bp) 
Fluorescent tag Ta (in oC) 
ARVC-8 
(DSP) 
DSP-M1 AC DSPMarker_1F tcgggagaattcccacatta 240 FAM 56 
 
 
  DSPMarker_1R tcctcacggatgtgctacaa  -  
 
 
DSP-M2 GT DSPMarker_2F tgaagggtcaggtgtcatca 229 HEX 56 
 
 
  DSPMarker_2R atatgccagggtggcttctt  -  
ARVC-9 
(PKP2) 
PKP2-M1 CA PKP2Marker_1F ctctcaaatagaaataggaagacaa 181 FAM 50 
 
 
  PKP2Marker_1R gggatacagtgtgtagcaattta  -  
 
 
PKP2-M2 TG PKP2Marker_2F ccaattcctgggctcaatag 341 HEX a 
 
 
  PKP2Marker_2R tcctcagacatacaggcagaag  -  
ARVC-11 
(DSC2) 
DSC2-M1 CA DSC2Marker_1F cattccagggccgtagataa 286 HEX a 
 
 
  DSC2Marker_1R gactgacagcagggacatca  -  
 
 
DSC2-M2 GT DSC2Marker_2F tcttggatcctgctctgtga 291 FAM a 
   DSC2Marker_2R gacaaacatacagctgccaaa  -  
Note: DSP = Desmoplakin; PKP2 = Plakophilin-2; DSC2 = Desmocollin-2; F = forward primer; R = reverse primer; Ta = Annealing temperature; a = Optimised by 












Table B-3: Primer sequences for mutation screening 
Name of primer 
 




Ta (in oC) 
C10orf97Exon1F aagctacttccaccgcttt 570 57 
C10orf97Exon1R gtgtctagaaagtccagcttca   
C10orf97Exon2F aaaggttccttgatccacac 470 57 
C10orf97Exon2R aagtcagggaacgcctatta   
C10orf97Exon3F gtgttctacagggctttcact 487 56 
C10orf97Exon3R cccactgatacttgactttctc   
C10orf97Exon4F catcattaacccattcttactattg 583 56 
C10orf97Exon4R gcatctgaaactgaagcatatc   
C10orf97Exon5F actgccgtagcatagctgaa 460 56 
C10orf97Exon5R caaattaatcctgaagcaatgg   
C10orf97Exon6F cctgccaagtaggtgttctt 516 56 
C10orf97Exon6R taagcaacgagtgagtgctg   
C10orf97Exon7F catt caaatctgagttacttgtgg 384 54 


































































HSPA14Exon1F gtgcgcactgtgcagttt 381 a 
HSPA14Exon1R gctctcaagcctgtggatg   
HSPA14Exon2+3F tttccacacagatggcaaag 452 a 




HSPA14Exon4+5R gtgcaatcactctgcttctc   




HSPA14Exon7F tgtgaagaatatgggctctgaa 447 a 
HSPA14Exon7R ttccatccagaaaggtttgg   
HSPA14Exon8F aaagggattaaactaagtgacttct 382 a 
HSPA14Exon8R tatccagtttccaagcaatg   
HSPA14Exon9F cggcctgattcactaattt 377 a 
HSPA14Exon9R ggttgataaatctcaaacaaaca   












HSPA14Exon10R aaatattctttcagtacccagagc   
HSPA14Exon11F tgtaataaatggtgagatttcctc 598 a 
HSPA14Exon11R ttaagacctgtcagtatacaaggtt   
HSPA14Exon12F tctctttgcctagtgtcctg 439 a 
HSPA14Exon12R ttcagaaatgagccttcataa   
HSPA14Exon13F tcagtgataaataagctttggtcct 371 a 
HSPA14Exon13R ttcaagatgcaaatgacttgagat   
HSPA14Exon14F cttgtttactgaaagccctcaag 547 a 
HSPA14Exon14R gcatcttactttctatgtggtcctg   
NMT2Exon1F  tggggagggacgaagagg 
 
344 see Table C-3 
NMT2Exon1R2  tcgtccagttccaggctc   
NMT2Exon1F2  
 
ggaggcactagagggagc 283 see Table C-6 
NMT2Exon1R  gccgaagaacccccagtc 
 
  
NMT2Exon2F  ttcctcacctacatcctaacacag 399 b 
NMT2Exon2R  tggcattcaacacacagtca 
 
  
NMT2Exon3F  cgtgcgtctgctcaagttta 
 
279 see Table C-4 
NMT2Exon3R  tgttgttgttgttgttcatcca   
NMT2Exon4+5+6F  tcactgaccactttggatgg 
 
732 58 
NMT2Exon4+5+6R  gcttggcctgcattcagta   
NMT2Exon7F  agcctgcattcttattcttgg 399 51 
NMT2Exon7R   aggttctagtctccatctctgct 
 
  
NMT2Exon8F  gtaacagccaagctgagacaa 297 a 
NMT2Exon8R ttcctcagacacaccagtcag   
NMT2Exon9F  ggctctgcagctctaactagc 489 56 












NMT2Exon10F  tgccgagaaagaagtgtgact 
 
400 a 
NMT2Exon10R  tcgcataaattccacctgtgt   
NMT2Exon11F  tcacggacgttaaatcctatt 448 a 





caggtgtgagctgagcctta 206 54 
NMT2Exon12R  ttcttctttggaatggcagtt   
FAM107BExon1F  gcactaccctaccctgaagc 
 
820 a 
FAM107BExon1R  gctgaaacattcgccaca   
FAM107BExon2F  aaacctcagttctttaaggtgtgg 
 
365 a 
FAM107BExon2R  cagatgtcgtgcctggaata   
FAM107BExon3F  agcccagttacattccaagc 
 
477 a 
FAM107BExon3R  gaaagccttaacaaagtgcaaga   
FAM107BExon4F  caccatgttgcctgctgtag 
 
390 a 
FAM107BExon4R  ctggcacgtctggtaaatcc   
FAM107BExon5F  ggaagtaaagttgtcagggacttt 369 a 



















































PTERExon6R aactgattaatatctcacagtggac   
RPP38Exon1F taacgaaacctgcactgctc 
 













RPP38Exon3aR ggcagggacacttctgctta   












































































C10orf38Exon8aR gtcccacttggagtgaggtt   
C10orf38Exon8bF cacctcccaggaatttagctc 600 60 
C10orf38Exon8bR ttggacagctcagcctgtagt   
C10orf38Exon8cF gggaccactcctatgtcagc 562 60 
C10orf38Exon8cR gctcgaggctctttctgct   
C10orf38Exon8dF gggagatgctttgtctctgc 489 60 





















































































































































































































































































































cagaggcatcggtaatacatttg   
 
  
MEIG1Exon1F  gctcctacctgggacctaca 
 
462 b 





ttgctctgtcacccagctt 618 b 
MEIG1Exon2R  ttggagtcgaatttccttcag 
 
  
MEIG1Exon3F  acagcataaggctgcaatgt 
 
692 b 
















atggcgaatccgtggtca 395 b 
C10orf111Exon1R  tataggctggcctccgaaca 
 
  
C10orf111Exon2F  ctttggaatcttagccctctg 
 
698 b 





acagcccatgtcattcttcc 243 b 
OLAHExon1R  gataatccaactataggctgtgcat 
 
  
OLAHExon2F  ttctcctttgtcatcaccactg 
 
386 b 
OLAHExon2R  cacctggctgagaaacctct 
 
  
OLAHExon3F  tttgccctttcttattgga 
 
380 b 
OLAHExon3R  accaggaaggaaagtcttga 
 
  
OLAHExon4F  caggctggagtacaatagca 
 
398 b 
OLAHExon4R  aaatttaaagcttctgtgagtcag 
 
  





ggccataattacctaacatgctg   
OLAHExon6F  tgttgtgtttatgatactgttcctt 
 
291 b 





ttcccagccttggtttaatg 374 b 
OLAHExon7R  tgtcttcccacataagcaacc 
 
  





gctgagattgcgccattg   
OLAHExon9F  
 
cgtacttcagggtgtcagctc 362 b 





tgtcttcgcctttccatttg 299 b 
ACBD7Exon1R  ggagccccacttaagcactc  
 
  













ACBD7Exon2+3+4R  aacagtatgcctctccctctaaa 
 
  
Note: F = forward primer; R = reverse primer; Ta = Annealing temperature; a = Optimised by 








































Appendix C: Methods 
C.1. Exclusion Mapping 
C.1.1. PCR Optimisation  
PCR was performed in 0.2ml tubes (Whitehead Scientific) in a total of 25µl containing 
50ng of DNA, 0.4µΜ of each primer, 0.2mM of each of the 4 dNTPs (Bioline, Celtic 
Molecular Diagnostics), 1x PCR Buffer (Promega Colorless GoTaq
R
 Flexi Buffer; pH 8.5, 
Whitehead Scientific), 1.5mM of MgCl2 (Promega, Whitehead Scientific), 0.5 unit of Taq 
polymerase (Promega GoTaq
R 
DNA Polymerase, Whitehead Scientific), made up with 
dH2O.  A total of eight tubes were set up each with the same DNA sample but a different 
annealing temperature.  Two negative controls, where dH2O replaced DNA, were included 
at the lowest annealing temperature and the highest annealing temperature to rule out 
contamination.  The PCR cycling conditions are given in Table C-1.  
 
Table C-1: PCR cycling conditions for microsatellite marker optimisation 
Step Temperature Time No. of cycles 
Initial Denaturation 94
o
C 5 minutes 1 
Denaturation 94
o
C 30 seconds 
Annealing 44-58
o
C* 30 seconds 
Extension 72
o





C 7 minutes 1 
*Each of the eight tubes had a different annealing temperature ranging from 44-58
o
C.   
 
C.1.2. Genotyping  
A volume of 8µl of Hi-Di™ Formamide (Applied Biosystems) and 0.25µl to 0.5µl of 
GeneScan™ 500 ROX™ Size Standard (Applied Biosystems) was aliquoted into wells of a 
96-well plate.  At least 2µl of neat or diluted PCR product was added to the wells.  The 
samples were denatured at 95
o
C for 5 minutes using a thermal cycler and then cooled 
immediately on ice.  The plate was loaded onto the ABI Prism
®
 3100 Genetic Analyzer 













C.2. Mutation Screening by Sequencing  
The primers for MEIG1, C10orf111, OLAH and ACBD7 and DNA for two affected and 
two unaffected family members were sent to the Central Analytical Facility, Stellenbosch 
University for PCR optimisation, amplification of patient DNA and sequencing. 
 
C.2.1. PCR Optimisation  
PCR was performed in 0.2ml tubes (Whitehead Scientific) in a total of 25µl containing 
100ng of DNA, 0.4µM of each primer, 0.2mM of each of the 4 dNTPs (Bioline, Celtic 
Molecular Diagnostics), 1x PCR Buffer (Promega Colorless GoTaq
® 
Reaction Buffer, 
Whitehead Scientific; pH 8.5., 1.5mM MgCl2), 0.5 unit of Taq polymerase (Promega 
GoTaq
® 
DNA Polymerase, Whitehead Scientific), made up with dH2O.  A total of 12 
tubes were set up each with the same DNA sample but a different annealing temperature.  
The PCR cycling conditions are given in Table C-2.   
 
Table C-2: PCR cycling conditions for optimisation 
Step Temperature Time No. of cycles 
Initial Denaturation 95
o
C 5 minutes 1 
Denaturation 95
o
C 30 seconds 
Annealing 50-60
o
C* 30 seconds 
Extension 72
o





C 7 minutes 1 
*Each of the 12 tubes had a different annealing temperature ranging from 50-60
o
C.   
 
C.2.2. Optimised PCR Conditions  
PCR of NMT2 exon 1 amplicon 1, exon 3, 4+5+6, 7 and 12 required further optimisation.  
















NMT2 exon 1 amplicon 1  
PCR was performed in 0.2ml tubes (Whitehead Scientific) in a total of 25µl containing 
100ng of DNA, 0.8µM of each primer (NMT2Exon1F & R), 0.2mM of each of the 4 
dNTPs (Kapa Biosystems), 1x PCR Buffer (KAPA2G Buffer A, Kapa Biosystems; 1.5mM 
MgCl2), 1x KAPAEnhancer 1 (Kapa Biosystems), 0.5 unit of Taq polymerase (KAPA2G 
Robust DNA Polymerase, Kapa Biosystems), made up with dH2O.  The PCR cycling 
conditions are given in Table C-3.   
 
Table C-3: PCR cycling conditions for NMT2 exon 1 amplicon 1 
Step Temperature Time No. of cycles 
Initial Denaturation 95
o
C 1 minute 1 
Denaturation 95
o
C 30 seconds 
Annealing 63
o
C 30 seconds 
Extension 72
o





C 1 minute 1 
 
NMT2 exon 3  
PCR was set up as in PCR optimisation (section C.2.1.).  The PCR cycling conditions are 
given in Table C-4. 
 
Table C-4: PCR cycling conditions for NMT2 exon 3 
Step Temperature Time No. of cycles 
Initial Denaturation 95
o
C 5 minutes 1 
Denaturation 95
o
C 30 seconds 
Annealing 59
o
C 1 minute 
Extension 72
o




















NMT2 exon 4+5+6 
PCR was set up as in PCR optimisation (section C.2.1.) except the PCR Buffer used was 
PCR optimization buffer C (Roche PCR Optimization Kit; pH 8.3., 2.0mM MgCl2).   
 
NMT2 exon 7 
PCR was set up as in PCR optimisation (section C.2.1.) except the PCR Buffer used was 
PCR optimization buffer D (Roche PCR Optimization Kit; pH 8.3., 2.5mM MgCl2).   
 
NMT2 exon 12 
PCR was set up as in PCR optimisation (section C.2.1.) except an additional 0.5mM 
MgCl2 was added.   
 
C.2.3. Sequencing  of NMT2 exon 1 amplicon 1 
Purification of PCR products 
Purification of PCR products was performed in 0.2ml tubes (Whitehead Scientific) in a 
total of 20µl containing 10µl of PCR product, 1 unit of SAP (Promega, Whitehead 
Scientific), 2 units of Exo I (New England Biolabs, Laboratory Specialist Services) made 
up with dH2O.  The tubes were incubated in a Labnet MultiGene Thermal Cycler 
(Whitehead Scientific) for 60 minutes at 37
o
C followed by 15 minutes at 75
o
C.   
 
Cycle sequencing 
Cycle sequencing was performed in 0.2ml tubes in a total of 20µl containing 5µl purified 
template, 3.2µM NMT2Exon1R or NMT2Exon1R2, 8µl BigDye
®
 Terminator v1.1 Ready 
Reaction Mix (Applied Biosystems), 2µl DMSO, made up with dH2O.  The thermal 
cycling was carried out on a Labnet MultiGene Thermal Cycler (Whitehead Scientific) 

























Purification of sequencing products and capillary electrophoresis 
The sequencing products were sent to the Central Analytical Facility, Stellenbosch 
University for purification and capillary electrophoresis.  
 
Analysis 
The electropherograms were analysed by eye to identify heterozygous variants.  To 
identify homozygous variants, the patients’ sequences were aligned to the wild type 
sequence.  BioEdit was used to align the sequences and the wild type sequence was 
obtained from the NCBI database. 
 
C.3. Mutation Screening by HRM 
C.3.1. PCR and HRM Optimisation 
PCR and HRM were performed in 0.2ml tubes (Whitehead Scientific) in a total of 25µl 
containing 100ng of DNA, 0.4µM of each primer, 1x Reaction Mix (Quantace SensiMix 
HRM
TM
, Celtic Molecular Diagnostics; contains reaction buffer, heat-activated Taq DNA 
Polymerase, dNTPs, 3mM MgCl2 and stabilisers), 1µl of EvaGreen
TM
 (Quantace, Celtic 








Temperature Time No. of cycles 
96
o
C 5 minutes 1 
96
o
C 30 seconds 
50
o
C 15 seconds 
60
o














Table C-6: PCR and HRM conditions  
Step Temperature Time No. of cycles 
Hold step  
(to activate enzyme) 
95
o
C 10 minutes 1  
Denaturation 95
o
C 5 seconds 
Annealing 55
o
C 10 seconds 
Extension 72
o











C.4. Mutation Screening by DHPLC 
C.4.1. PCR Optimisation 
PCR was performed in 0.2ml plates in a total of 50µl containing 100ng of DNA, 0.4µM of 
each primer (Invitrogen), 0.04mM of each of the 4 dNTPs (Invitrogen), 1x PCR Buffer 
(Promega Colorless Go Taq® Flexi Buffer, pH 8.5.), 1.5mM MgCl2 (Promega), 1 unit of 
Taq polymerase (Promega GoTaq® DNA Polymerase), made up with dH2O.  A total of 
12 tubes were set up each with the same DNA sample but a different annealing 
temperature.  The PCR cycling conditions are given in Table C-7.  The melting 
temperature (Tm) was calculated for each primer using the formula: Tm = 4(G + C) + 2(A 
+ T).  The annealing temperature (Ta) was then calculated by subtracting 5
o
C from the 
lowest melting temperature for the primer pair.  The calculated annealing temperatures 


















Table C-7: PCR cycling conditions for optimisation 
Step Temperature Time No. of cycles 
Initial Denaturation 95
o
C 2 minutes 1 
Denaturation 95
o
C 30 seconds 
Annealing 50-60
o
C* 30 seconds 
Extension 72
o





C 5 minutes 1 
Hold 10
 o
C - 1 
* Each of the 12 tubes had a different annealing temperature ranging from 50-60
o
C.   
 
C.4.2. Optimised PCR Conditions for RPP38 exon 1 
PCR of RPP38 exon 1 required further optimisation.  The final, optimised conditions for 
this exon are as follows: 
 
PCR was performed in 0.2ml tubes in a total of 50µl containing 100ng of DNA, 0.4µM of 
each primer (Invitrogen), 0.04mM f each of the 4 dNTPs (Invitrogen), 1x PCR Buffer 
(QIAGEN; 1.5mM MgCl2), 1 unit of Taq polymerase (QIAGEN), 1x Q-Solution, made up 
with dH2O.  A total of 12 tubes were set up each with the same DNA sample but a 
























Table C-8: PCR cycling conditions for RPP38 exon 1 
Step Temperature Time No. of cycles 
Initial Denaturation 94
o
C 3 minutes 1 
Denaturation 94
o
C 30 seconds 
Annealing 66
o
C* 30 seconds 
Extension 72
o





C 30 seconds 
Annealing 55
o
C 30 seconds 
Extension 72
o





C 7 minutes 1 
Hold 10
 o
C - 1 
*Ta decreases by 1
o
C every cycle 
 
C.4.3. Sequencing 
Purification of PCR products 
A volume of 5µl of PCR product was mixed with 2µl of ExoSAP-IT (Amersham 
Bioscience).  ExoSAP-IT contains Exo I and SAP.  The samples were incubated on a 
thermal cycler (GeneAmp PCR System 9700) at 37
o
C for 15 minutes and then incubated 
at 80
o
C for 15 minutes. 
 
Cycle sequencing 
Cycle sequencing was performed in 0.2ml tubes in a total of 10µl containing 1µl purified 
template, 0.4µM forward or reverse primer, 1µl BigDye
®
 Terminator v1.1 Ready Reaction 
Mix (Applied Biosystems), 1.5µl Sequencing Buffer (Applied Biosystems), made up with 
dH2O.  The thermal cycling was carried out on a GeneAmp
R
 PCR System 9700 and the 























Purification of sequencing products 
The Montage SEQ96 Sequencing Reaction Cleanup Kit (Millipore) was used to purify the 
sequencing products.  A volume of 20µl of Injection Solution was added the sequencing 
product.  The sequencing product was transferred to a SEQ plate well.  The SEQ plate was 
placed on a vacuum manifold with ice packs and a vacuum (20-25” Hg) was applied for 3 
minutes 40 seconds.  The SEQ plate was removed from the manifold and the bottom of the 
SEQ plate was blotted on tissue paper to remove excess liquid.  A volume of 25µl of 
Injection Solution was added to the well.  The SEQ plate was returned to the vacuum 
manifold and a vacuum was applied for 4 minutes.  The SEQ plate was removed from the 
manifold and the bottom of the SEQ plate was blotted on tissue paper.  A volume of 20µl 
of Injection Solution was added to the well and the SEQ plate was put on a microplate 
shaker at speed 2.5/3 for 10 minutes.  The purified sequencing product was transferred 
from the well into a clean tube. 
 
Capillary electrophoresis 
A volume of 5µl of purified sequencing product was added to 15µl HiDi Formamide 
(Applied Biosystems).  The sample was denatured at 95
o
C for 3 minutes on a thermal 
cycler and then rapidly chilled by placing the sample on ice or in a -20
 o
C freezer for 15 
minutes.  Sequencing was performed on the ABI Prism
R
 310 Genetic Analyzer (Applied 
Biosystems) and analysed using the Sequence Analysis version 5.2.0 software (Applied 
Biosystems).   
Temperature Time No. of cycles 
96
o
C 1 minute 1 
96
o
C 10 seconds 
50
 o
C 5 seconds 
60
 o


















The electropherograms were analysed by eye to identify heterozygous variants.  To 
identify homozygous variants, the patients’ sequences were aligned to the wild type 
sequence.  BioEdit was used to align the sequences and the wild type sequence was 

































Appendix D: Gel Formulas  
1% (w/v) Agarose gel with ethidium bromide (100ml) 
1g Agarose (SeaKem
®
 LE Agarose, Whitehead Scientific)  
100ml 1x TBE buffer (Appendix E) 
6µl Ethidium bromide (10mg/ml) 
 
3% (w/v) MS-8 Agarose gel with ethidium bromide (300ml) 
9g Agarose MS-8 
300ml 1x TBE buffer (Appendix E) 
18µl Ethidium bromide (10mg/ml) 
 
Stir the TBE buffer with a stirrer bar while adding Agarose MS-8.  Stir for 5 minutes.  
Heat the mixture in a microwave for a few minutes at a time.  Add the ethidium bromide 
to the solution, mix and pour into a casting tray.  Allow to solidify.  To achieve the best 
resolution, store the gel at 4
o
C for 30 minutes before use. 
 
2% (w/v) Agarose gel with ethidium bromide (100ml) 
2g Agarose (Vivantis)  
100ml 1x TBE buffer (Invitrogen) or 1x TAE buffer (EuroClone) 
























Appendix E: Solutions and Buffers 
10x Tris Borate EDTA (TBE) buffer (2L) 
216g Tris  
110g Boric acid 
14.8g EDTA 
Make up to 2L with dH2O 
 
Green GoTaq® Flexi Buffer 
The buffer contains a blue and a yellow dye.  In a 1% agarose gel the blue dye migrates at 
the same rate as a 3-5kb DNA fragment and the yellow dye migrates at a rate faster than 






Agarose Loading Dye 
0.125g Bromophenol blue 
20g Sucrose 


















Appendix F: DNA Ladders 
 
 












































































Appendix G: Candidate Genes in the Chromosome 4 
Linkage Interval 
 
Table G-1: Ensembl Gene IDs and HGNC Symbols for the 90 candidate genes in the 
chromosome 4 linkage interval 




ENSG00000251166  OR4D12P 
ENSG00000234386  OR7E84P 
ENSG00000197701  ZNF595 
ENSG00000250312  ZNF718 
ENSG00000198155  ZNF732 
ENSG00000198155  ZNF876P 
ENSG00000131127  ZNF141 
ENSG00000182903  ZNF721 
ENSG00000182903  ABCA11P 
ENSG00000174227  PIGG 
ENSG00000133256  PDE6B 
ENSG00000169020  ATP5I 
ENSG00000215375  MYL5 
ENSG00000169026  MFSD7 
ENSG00000185619  PCGF3 
ENSG00000168993  CPLX1 
ENSG00000178950  GAK 
ENSG00000127419  TMEM175 
ENSG00000145214  DGKQ 
ENSG00000145217  SLC26A1 
ENSG00000127415  IDUA 
ENSG00000127418  FGFRL1 
ENSG00000178222  RNF212 












ENSG00000159692  CTBP1 
ENSG00000196810  C4orf42 
ENSG00000090316  MAEA 
ENSG00000163945  KIAA1530 
ENSG00000179979  CRIPAK 
ENSG00000235608  NKX1-1 
ENSG00000174137  FAM53A 
ENSG00000163950  SLBP 
ENSG00000168936  TMEM129 
ENSG00000013810  TACC3 
ENSG00000068078  FGFR3 
ENSG00000168924  LETM1 
ENSG00000109685  WHSC1 
ENSG00000185049  WHSC2 
ENSG00000185818  NAT8L 
ENSG00000243449  C4orf48 
ENSG00000130997  POLN 
ENSG00000214367  HAUS3 
ENSG00000123933  MXD4 
ENSG00000159733  ZFYVE28 
ENSG00000063978  RNF4 
ENSG00000125386  FAM193A 
ENSG00000168884  TNIP2 
ENSG00000087266  SH3BP2 
ENSG00000087274  ADD1 
ENSG00000109736  MFSD10 
ENSG00000087269  NOP14 
ENSG00000125388  GRK4 
ENSG00000197386  HTT 
ENSG00000188981  C4orf44 
ENSG00000159788  RGS12 












ENSG00000175920  DOK7 
ENSG00000163956  LRPAP1 
ENSG00000184160  ADRA2C 
ENSG00000163982  OTOP1 
ENSG00000132406  TMEM128 
ENSG00000145220  LYAR 
ENSG00000168826  ZBTB49 
ENSG00000168818  STX18 
ENSG00000163132  MSX1 
ENSG00000170891  CYTL1 
ENSG00000152953  STK32B 
ENSG00000082929  C4orf6 
ENSG00000173040  EVC2 
ENSG00000072840  EVC 
ENSG00000072832  CRMP1 
ENSG00000181215  C4orf50 
ENSG00000152969  JAKMIP1 
ENSG00000109501  WFS1 
ENSG00000074211  PPP2R2C 
ENSG00000013288  MAN2B2 
ENSG00000179010  MRFAP1 
ENSG00000163993  S100P 
ENSG00000178988  MRFAP1L1 
ENSG00000186222  CNO 
ENSG00000170871  KIAA0232 
ENSG00000132405  TBC1D14 
ENSG00000173013  CCDC96 
ENSG00000173011  TADA2B 
ENSG00000109519  GRPEL1 
ENSG00000207642  MIR571 
ENSG00000216105  MIR943 
 
 
